Paradigm Biopharmaceuticals Limited
A B N 9 4 1 6 9 3 4 6 9 6 3
2019 ANNUAL REPORT
PARADIGM BIOPHARMACEUTICALS LIMITED
C O N T E N T S
Corporate Directory
Chairman’s Report
Managing Director’s Review
Directors' Report
Remuneration Report
Auditor’s Independence Declaration
Consolidated Financial Statements & Notes
Directors' Declaration
Independent Auditor’s Report
Shareholder Information
Corporate Governance Statement
Page
2
3
4
8
13
20
21
45
46
49
51
General Information
The Financial Statements cover Paradigm Biopharmaceuticals Limited as a Consolidated Entity consisting of Paradigm
Biopharmaceuticals Limited and the entities it controlled at the end of, or during the year. The Financial Statements are
presented in Australian dollars, which is Paradigm Biopharmaceuticals Limited's functional and presentation currency.
Paradigm Biopharmaceuticals Limited is a listed public company limited by shares, incorporated and domiciled in Australia.
A description of the nature of the Consolidated Entity's operations and its principal activities are included as part of the
Financial Statements.
The Financial Statements were authorised for issue, in accordance with a resolution of Directors, on 30 August 2019. The
Directors have the power to amend and reissue the Financial Statements.
PARADIGM BIOPHARMACEUTICALS LIMITED
C O R P O R A T E D I R E C T O R Y
Directors
Mr Graeme Kaufman
Mr Paul Rennie
Mr Christopher Fullerton
Mr John Gaffney
–
–
–
–
Chairman & Non-Executive Director
Managing & Executive Director
Non-Executive Director
Non-Executive Director
Company Secretary
Mr Kevin Hollingsworth
Principal Place of Business
Level 15, 500 Collins Street
Melbourne, VIC 3000
Registered Office
C/-Hollingsworth & Co Pty Ltd
Level 2, 517 Flinders Lane
Melbourne, VIC 3000
Auditor
RSM Australia Partners
Level 21
55 Collins Street
Melbourne, VIC 3000
Solicitors
K&L Gates
Level 25, South Tower, 525 Collins Street
Melbourne, VIC 3000
Share Registry
Computershare Limited
Yarra Falls, 452 Johnston Street
Abbotsford, VIC 3067
Telephone: (61-3) 1300 137 328
Bankers
Commonwealth Bank
Level 20, Tower One, Collins Square
727 Collins Street
Melbourne, VIC 3008
Stock Exchange
ASX Limited
Level 4, North Tower, 525 Collins Street
Melbourne, VIC 3000
ASX Code: PAR
Website
www.paradigmbiopharma.com
2
PARADIGM BIOPHARMACEUTICALS LIMITED
C H A I R M A N ’ S R E P O R T
Dear Shareholders,
I am pleased to present the 2019 Annual Report for Paradigm Biopharmaceuticals Limited.
The Company listed on the Australian Securities Exchange (ASX: PAR) on 19 August 2015. Our business model is to
repurpose the historic drug injectable pentosan polysulfate sodium (iPPS) for new clinical indications.
During the last financial year, the Company has conducted two Phase 2 clinical trials.
The first is a Phase 2b randomised, double-blind, placebo-controlled multicentre clinical trial investigating iPPS in subjects
with osteoarthritis and concurrent bone marrow edema lesions. The recruitment of the 124 subjects (total population) into
the clinical trial commenced in November 2017 and concluded August 2018. The primary endpoint was reduction in pain
from baseline and it was successfully met (P<0.0001). Paradigm is now preparing for a pivotal Phase 3 clinical trial to be
conducted in the USA, EU and Australia. There is a global trend for safe and effective non-opioid and non-steroid pain relief
for chronic disease such as osteoarthritis which presents a huge market opportunity for Paradigm’s iPPS.
The Company also commenced, July 2017, a Phase 2a randomised, double-blind, placebo controlled clinical study
investigating iPPS to treat people recently infected with the alpha virus - Ross River virus. The alpha virus is transmitted to
humans via infected mosquitos. The clinical trial successfully concluded February 2019. Like our OA program this program
is also a very exciting commercial opportunity as there are currently no registered vaccines or therapeutics to treat the ten
thousand cases of Ross River infections in Australia each year nor the closely related alpha virus Chikungunya virus.
Chikungunya virus is endemic in many countries and there are millions of cases diagnosed each year again with no
registered vaccines or therapeutics to treat this debilitating disease.
In addition to the two lead clinical indications, the Company has generated innovative PPS proof-of-concept, nonclinical and
clinical data for a new indication for MPS which further expands our pipeline.
The Company continues to execute on its drug repurposing business strategy. Last financial year the Company continued
the prudent use of shareholder funds spending directly 70% of expenditure on the clinical trial programs.
Given the success in the two Phase 2 clinical trials, the Paradigm Board has made the decision to focus our resources on
the lead clinical programs of osteoarthritis, alpha virus infection and the rare disease mucopolysacharaidosis (MPS).
With two Phase 2 clinical trials reading out this year it is an exciting time for the Company, and I acknowledge the terrific
support of our shareholders which is so important to the Company. I also thank our CEO, Paul Rennie, and his management
team for the very significant outcomes they have achieved in the past 12 months since my last report.
On behalf of the Directors,
Graeme Kaufman
Chairman
Melbourne, Victoria
30 August 2019
3
PARADIGM BIOPHARMACEUTICALS LIMITED
M A N A G I N G D I R E C T O R ’ S R E V I E W
Dear Shareholders,
I am pleased to report on the progress made by the executive management team of Paradigm Biopharmaceuticals Limited
and its controlled entities (“Paradigm”) during the past 12 months.
Paradigm’s business plan is to repurpose the historic drug injectable Pentosan Polysulfate Sodium (iPPS) for new indications
with unmet medical needs. We maintain a high focus on prudently managing shareholders funds while at the same time
rapidly and efficiently executing on our clinical development plans. Over the past 12 months Paradigm has completed two
Phase 2 clinical trials and in-licensed new intellectual property from the Icahn School of Medicine, Mt Sinai New York.
Clinical Development
1. Bone Marrow Edema Lesions – Osteoarthritis
Osteoarthritis (OA) is the most prevalent form of joint disease, affecting as much as 13% of the world’s population. An
estimated 33 million people in the USA and over 3 million people in Australia suffer from degenerative osteoarthritis.
“The presence of bone marrow edema lesions (BMELs) has been linked to chronic pain and progression of OA. The
prevalence and severity of BMELs are associated with less cartilage loss over 2 years. Moreover, severity of BMLs was
positively associated with risk of knee joint replacement. This provides further support for the importance of BMELs in
identifying those with OA most likely to progress. Identifying factors that prevent or reduce the severity of BMELs may
provide an important target in the prevention of disease progression and treatment of OA, and the subsequent need for total
knee replacement surgery”2.
In the US alone, the financial burden of OA has been estimated to be $81 billion in medical costs and $128 billion in total
cost, given approximately 21 million people with OA associated limitations, 36 million outpatient visits and 750,000
hospitalizations per year3.
Opioid medicines are used by a large percentage of patients who have advanced knee, hip, or spine osteoarthritis to manage
their chronic pain. Dr Scott Gottlieb, M.D., ex-Commissioner of the U.S. Food and Drug Administration said on 14 May
2018, “The biggest public health crisis facing FDA is opioid addiction. Not a day goes by in my role at FDA without hearing
stories of the emotional, physical, and financial toll this epidemic is taking on Americans”4.
iPPS is a non-opioid drug which is safe and has potential to distrupt the pharmaceutical market for the treatment for chronic
pain arising from osteoarthritis.
The Phase 2b results were a resounding success. They demonstrated that iPPS achieved clinically meaningful and
statistically significant results in the primary symptoms of osteoarthritis (pain and joint function) and also showed
improvements in the structural changes of the joint. Paradigm is pleased to report the Phase 2b clinical trial achieved both
symptomatic and radiographic (MRI) improvement.
Given the success of the Phase 2b clinical trial, Paradigm will apply to the US FDA for a pivotal Phase 3 clinical trial with a
Pre-IND meeting with the US FDA targetted for Q3 CY 2019.
2. Alphavirus – Ross River virus (RRV) and Chikungunya virus (CHIKV)
Alphavirus disease causes crippling pain and joint arthritis, which often has an extended duration of months or years. In
2016 Chikungunya virus (CHIKV) expanded in the Americas, with approximately 1 million cases reported there and again
another 1 million new cases in the first half of 2017. Ross River Virus (RRV) continues to circulate in the South Pacific.
Currently, there are no registered specific treatments for Alphavirus disease, and the increasing spread of the viral infection
highlights an urgent need for novel therapeutic interventional strategies. In the preclinical research RRV infection was
demonstrated to damage the articular cartilage, including a loss of proteoglycans within the joint. PPS reduced the severity
of both RRV- and CHIKV-induced muscle and joint pain, including a reduction in inflammation and joint swelling. The
preclinical data along with 20 people with RRV treated with PPS in a pilot study suggested PPS was safe, well tolerated and
had effect on the pain and viral arthritis associated with an alphavirus infection.
The encouraging results from the preclinical and pilot human study provided the rationale for the Phase 2a randomised,
double-blind, placebo controlled clinical study which commenced treating study participants in August 2017.
Primary end point met.
The secondary end points demonstrated injectable pentosan polysulfate sodium (iPPS) reduced RRV disease
symptoms compared to placebo.
At 3 months follow-up 72.7% (8/11) of subjects in the iPPS group showed near remission of symptoms based on
Rapid-3 disease assessment in contrast to 14.3% (1/7) in the placebo group.
Current treatments for RRV are pain relief (paracetamol) and anti-inflammatories (NSAID’s). No current treatment has
been shown to shorten the duration or alter the course of RRV.
The RRV clinical data will support discussions with US Department of Defense and pharmaceutical companies with
tropical disease programs.
4
PARADIGM BIOPHARMACEUTICALS LIMITED
M A N A G I N D I R E C T O R ’ S R E V I E W ( C O N T ’ D )
2. Alphavirus – Ross River virus (RRV) and Chikungunya virus (CHIKV) (cont’d)
5
PARADIGM BIOPHARMACEUTICALS LIMITED
M A N A G I N D I R E C T O R ’ S R E V I E W ( C O N T ’ D )
2. Alphavirus – Ross River virus (RRV) and Chikungunya virus (CHIKV) (cont’d)
We are very pleased to report this pilot RRV study yielded very promising safety data and key efficacy outcomes
especially the outcome of the reduction of disease symptoms in this debilitating chronic phase of the disease. At 3
months follow-up 72.7% (8/11) of subjects in the iPPS group showed near remission of symptoms based on Rapid-3
disease assessment in contrast to 14.3% (1/7) in the placebo group.
The human data on the effects of iPPS in RRV induced arthralgia together with our preclinical work on CHIKV will progress
our commercial discussions with US Department of Defense.
3. Allergic Rhinitis / hay fever
Intranasal corticosteroids and anti-histamines are the current first line therapies used to treat the symptoms of allergic rhinitis.
Paradigm developed a non-steroid-based intranasal PPS spray and conducted a Phase 1 safety study and a Phase 2a
randomised double-blind placebo cross over clinical study. In May 2017, Paradigm reported the Phase 2 study failed to
meet its primary clinical endpoints. This was an unexpected outcome, and the clinical data is being reviewed by industry
experts to determine our next steps with the Allergic Rhinitis program.
Paradigm remains committed to its respiratory asset. Further R&D will be undertaken to identify the reasons for the lack of
translation from the preclinical Allergic Rhinitis results into the Phase 2 human clinical trial. Depending on Paradigm’s
findings the Allergic Rhinitis Phase 2 study could be repeated, or the Allergic Rhinitis program may be terminated in
preference to its Asthma or Chronic Obstructive Pulmonary Disease (COPD) programs.
4. Mucopolysaccharidosis (MPS)
During the past 12 months, Paradigm in-licensed patents claiming the use of iPPS to treat the rare disease of
mucopolysaccharidosis (MPS). MPS is a rare genetic disease which is currently treated with enzyme replacement therapy
(ERT). ERT is known to have limited effects on some organs, especially the skeletal system. In MPS animal models PPS
reduces the concentrations of glycosaminoglycans (GAGs) in tissues and body fluids and improves cartilage and bone
pathologies. A Phase 2a clinical trial (Hennermann J et al 2016)1 conducted in Germany demonstrated that MPS patients
had reduced urinary GAG levels, reduced pain and improved joint mobility. In the Phase 2a clinical trial all subjects received
ERT and iPPS. IPPS has the potential to be adjunctive therapy with ERT for MPS sufferers.
Research & Development
A focused Research & Development (R&D) program will be undertaken to identify and develop second generation products
and the pain reducing mechanism of action of iPPS with osteoarthritis. This R&D program will be managed by Paradigm’s
Chief Scientific Officer. Paradigm will continue to outsource its R&D to world-class research laboratories and CRO’s. In line
with Paradigm’s publication policy it will publish the pre-clinical studies in peer-reviewed scientific journals.
6
PARADIGM BIOPHARMACEUTICALS LIMITED
M A N A G I N D I R E C T O R ’ S R E V I E W ( C O N T ’ D )
Intellectual Property
BME Patent: Paradigm’s Bone Marrow Edema Lesion (BMEL) patent family has expanded with three new patents filed
during the past 12 months. The new patents include new indications within the BMEL patent family.
Respiratory Patent: Paradigm’s respiratory patent covers the use of PPS for treating Allergic Rhinitis, Allergic Asthma and
COPD. The Respiratory patent is now granted in Australia, New Zealand, China, Canada and Europe.
Managing shareholder funds and delivering on our clinical milestones continue to be our top corporate priorities. The
significant achievements in the past 12 months have been made possible by our highly talented and productive employees
and consultants. I would also like to acknowledge the outstanding support of Paradigm’s clinical & regulatory staff, scientific
& medical professionals and our manufacturing partners.
Paul Rennie
Chief Executive Officer
References:
1Treatment with pentosan polysulphate in patients with MPS I: results from an open label, randomized, monocentric phase
II study. Hennermann J et al.
2 Rheumatology; Bone marrow lesions in people with knee osteoarthritis predict progression of disease and joint
replacement: a longitudinal study; Tanamas S K et al 2010.
3 National Institute of Health; Emerging drugs for osteoarthritis; Hunter DJ and Matthews G 16(3): 479–491; 2011
September.
4 https://blogs.fda.gov/fdavoice/index.php/2018/05/addressing-needs-of-patients-while-stemming-the-tide-of-the-opioid-
crisis/
7
PARADIGM BIOPHARMACEUTICALS LIMITED
D I R E C T O R S ’ R E P O R T
Directors present their report together with the financial report of Paradigm Biopharmaceuticals Limited and its controlled
entities (“Paradigm”), for the financial year ended 30 June 2019, and the Auditor’s Report thereon.
DIRECTORS
Information on Directors
The Directors of Paradigm at any time during or since the end of the financial year are:
Graeme Kaufman, Chairman and Non-Executive Director (Appointed on 02 May 2014)
Graeme Kaufman BSc, MBA, has wide ranging experience across the biotechnology sector, spanning scientific, commercial
and financial areas. His experience with CSL Limited, Australia’s largest biopharmaceutical company included responsibility
for all of their manufacturing facilities, and the operation of an independent business division operating in the high technology
medical device market. As CSL’s General Manager Finance, Mr Kaufman had global responsibility for finance, strategy
development, human resources and information technology. Mr Kaufman has also served as an Executive Director of ASX-
listed Circadian Technologies and a Non-Executive Director of Amrad Corporation and held the role of Executive Vice
President Corporate Finance with Mesoblast Limited until 2013. He is currently a Non-Executive Director of IDT Australia
Limited.
Paul Rennie, Managing and Executive Director (Appointed on 02 May 2014)
Paul Rennie BSc, MBM, Grad Dip Commercial Law, MSTC, has sales, marketing, business development, operational and
IP commercialisation experience in the biopharmaceutical sector. Paul’s experience includes working for Boehringer
Mannheim (now Roche Diagnostics), Merck KGGA as national sales and marketing manager and Soltec (FH Faulding Ltd)
as their Director of business development. Paul also led the commercialisation of Recaldent® a novel biopharmaceutical
arising from research at the dental school, University of Melbourne. Paul took an R&D project from the laboratory bench to
a commercial product now marketed globally as an additive to oral care products. More recently Paul worked in a number
of positions with Mesoblast Ltd. Paul was the inaugural COO and moved into Executive Vice President New Product
Development for the adult stem cell company. For the past 4 years, Paul has worked full time at Paradigm
Biopharmaceuticals Limited.
Christopher Fullerton, Non-Executive Director (Appointed on 30 September 2014)
Christopher Fullerton, BEc, has extensive experience in investment, management and investment banking and is a qualified
chartered accountant. He is an investor in listed equities and private equity and his current unlisted company directorships
cover companies in the property investment and agriculture sectors. Mr Fullerton’s exposure to and experience in the fields
of biotechnology and health care technology was gained through his Non-Executive chairmanships of Bionomics Limited,
Cordlife Limited and Health Communication Network Limited. He is currently a Non-Executive Director of XTEK Ltd.
John Gaffney, Non-Executive Director (Appointed on 30 September 2014)
John Gaffney LL.M is a lawyer with over 30 years’ experience and has undertaken the AICD Company Directors qualification.
He brings to the board a compliance and corporate governance background and is experienced in financial services
compliance. John also has corporate and commercial experience having worked with a major national law firm as a senior
lawyer and also practised as a Barrister at the Victorian Bar. Previously John has been a Non-Executive Director of a US
based biotechnology company. He is currently a Non-Executive Director of SelfWealth Ltd.
COMPANY SECRETARY
Kevin Hollingsworth, Company Secretary (Appointed on 02 May 2014)
Kevin Hollingsworth, FCPA, FCMA, CGMA, in addition to his duties at Paradigm, serves as Principal of Hollingsworth
Financial Services. Prior to that he served as Chief Financial Officer and Company Secretary of Mesoblast Limited (ASX:
MSB). At Alpha Technologies Corporation Limited (ASX: ASU), Kevin Hollingsworth served as a Non-Executive Director.
He has served as National President of CIMA Australia, State Councillor for CPA Australia and Chairman of the National
and Victorian Industry and Commerce Accountants Committees. He is a Chartered Global Management Accountant and
Fellow of CPA Australia and Chartered Management Accountants.
8
PARADIGM BIOPHARMACEUTICALS LIMITED
D I R E C T O R S ’ R E P O R T ( C O N T ’ D )
DIRECTORSHIPS IN OTHER LISTED ENTITIES
Directorships of other listed entities held by Directors of Paradigm during the last 3 years immediately before the end of the
financial year are as follows:
Director
Company
Graeme Kaufman
Christopher Fullerton
John Gaffney
IDT Australia Limited
Bionomics Ltd
XTEK Ltd
SelfWealth Ltd
DIRECTORS’ MEETINGS
Period of directorship
From
To
01-Jun-13
18-Sep-12
24-Apr-18
23-Nov-17
Current
01-Sep-16
Current
Current
The number of Directors’ meetings (including meetings of committees of Directors) and the number of meetings attended
by each of the Directors of Paradigm during the financial year are:
Board
Nomination &
Remuneration
Committee
Audit & Risk
Committee
Director
Held
Attended
Held
Attended
Held
Attended
Graeme Kaufman
Paul Rennie
Christopher
Fullerton
John Gaffney
9
9
9
9
9
9
9
9
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
Committee membership
As at the date of the report, Paradigm had a Nomination and Remuneration Committee and an Audit and Risk Committee
of the Board of Directors. Members acting on the committees of the Board during the financial year were:
Nomination &
Remuneration
Committee
Graeme Kaufman (Chairman)
Paul Rennie
Christopher Fullerton
John Gaffney
PRINCIPAL ACTIVITIES
Audit & Risk
Committee
Christopher Fullerton (Chairman)
Graeme Kaufman
John Gaffney
The principal activities of Paradigm are researching and developing therapeutic products for human use. It is a drug
repurposing company which seeks to find new uses for old drugs, thereby reducing the cost and time to bring therapeutics
to market.
9
PARADIGM BIOPHARMACEUTICALS LIMITED
D I R E C T O R S ’ R E P O R T ( C O N T ’ D )
OPERATING REVIEW
Paradigm made a loss for the financial year ended 30 June 2019 of $15,627,544 (2018: Loss of $6,190,232).
Consolidated revenue including other income during the period was $3,245,628 (2018: $2,736,400). This revenue included
interest of $261,710 (2018: $53,899), and an R&D tax incentive of $2,983,918 (2018: $2,682,501).
The consolidated total expenses for the period were $18,873,172 (2018: $8,926,632).
The research and development expenses for the period were $7,896,708 (2018: $6,594,575).
The other operating expenses during the period were $4,047,480 (2018: $2,332,057).
The impairment loss during the period was $6,928,984 (2018: Nil).
Basic and diluted net loss per share increased to 10.93 cents (2018: 5.46 cents) due to the increased loss and increased
number of shares.
ENVIRONMENTAL REGULATION
Paradigm’s operations are not regulated by any significant environmental law of the Commonwealth or of a state or territory
of Australia.
SIGNIFICANT CHANGES IN THE STATE OF AFFAIRS
There have been no significant changes in the state of affairs of the entities in Paradigm during the year.
DIVIDENDS
No dividends were declared or paid since the start of the financial year. No recommendation for payment of dividends has
been made.
EVENTS SUBSEQUENT TO BALANCE DATE
No other matters or circumstances have arisen since balance date which have impacted or are likely to impact Paradigm’s
operations, results and state of affairs in future financial years.
LIKELY DEVELOPMENTS
There are no likely developments.
CORPORATE GOVERNANCE
The Corporate Governance Statement appears on Paradigm’s website at:
http://www.paradigmbiopharma.com/investors/corporate-governance
DIRECTORS’ INTERESTS
The relevant interest of each Director in the shares and options issued by Paradigm at the date of this report is as follows:
Director
Graeme Kaufman
Paul Rennie
Christopher Fullerton
John Gaffney
Ordinary
shares
2,074,250
23,379,935
960,000
703,250
10
PARADIGM BIOPHARMACEUTICALS LIMITED
D I R E C T O R S ’ R E P O R T ( C O N T ’ D )
INDEMNIFICATION AND INSURANCE OF OFFICERS
Indemnification
Paradigm has agreed to indemnify the current Directors of Paradigm against all liabilities to another person (other than
Paradigm or a related body corporate) that may arise from their position as Directors of Paradigm, except where the liability
arises out of conduct involving a lack of good faith.
The agreement stipulates that Paradigm will meet to the maximum extent permitted by law, the full amount of any such
liabilities, including costs and expenses.
Insurance premiums
Paradigm paid a premium during the year in respect of a Director and officer liability insurance policy, insuring the Directors
of Paradigm, the Company Secretary, and all Executive Officers of Paradigm against a liability incurred as such a Director,
Secretary or Executive Officer to the extent permitted by the Corporations Act 2001. The Directors have not included details
of the nature of the liabilities covered or the amount of the premium paid in respect of the Directors’ and Officers’ liability
and legal expenses insurance contracts, as such disclosure is prohibited under the terms of the contract.
Shares under option
Unissued ordinary shares of Paradigm under option at the date of this report are as follows:
Grant date
18/05/2018
07/05/2018
16/11/2017
27/09/2017
19/01/2017
Expiry date
18/05/2021
07/05/2021
15/11/2020
27/09/2020
19/01/2020
Exercise
price
Number
under option
$0.65
$0.45
$0.31
$0.45
$0.40
1,000,000
1,000,000
192,500
2,000,000
2,000,000
No person entitled to exercise the options had or has any right by virtue of the option to participate in any share issue of
the company or of any other body corporate.
Shares issued on the exercise of options
The following ordinary shares of Paradigm were issued during the year ended 30 June 2019 and up to the date of this
report on the exercise of options granted:
Grant date
07/08/2015
07/08/2015
16/11/2017
Proceedings on behalf of Paradigm
Exercise
price
Number of
shares issued
$0.375
$0.50
$0.31
952,382
1,357,142
157,500
No person has applied to the Court under section 237 of the Corporations Act 2001 for leave to bring proceedings on behalf
of Paradigm, or to intervene in any proceedings to which Paradigm is a party for the purpose of taking responsibility on
behalf of Paradigm for all or part of those proceedings.
Non-audit services
Paradigm’s auditor, RSM Australia, was appointed in July 2014 for audit services and also provided taxation services during
the year.
Details of the amounts paid or payable to the auditor for non-audit services provided during the financial year by the auditor
are outlined in note 24 to the financial statements.
The Directors are satisfied that the provision of non-audit services during the financial year, by the auditor (or by another
person or firm on the auditor's behalf), is compatible with the general standard of independence for auditors imposed by the
Corporations Act 2001.
11
PARADIGM BIOPHARMACEUTICALS LIMITED
D I R E C T O R S ’ R E P O R T ( C O N T ’ D )
Non-audit services (cont’d)
The Directors are of the opinion that the services as disclosed in note 24 to the financial statements do not compromise the
external auditor's independence requirements of the Corporations Act 2001 for the following reasons:
all non-audit services have been reviewed and approved to ensure that they do not impact the integrity and
objectivity of the auditor; and
none of the services undermine the general principles relating to auditor independence as set out in APES 110
Code of Ethics for Professional Accountants issued by the Accounting Professional and Ethical Standards Board,
including reviewing or auditing the auditor's own work, acting in a management or decision-making capacity for
Paradigm, acting as advocate for Paradigm or jointly sharing economic risks and rewards.
Officers of Paradigm who are former partners of RSM Australia
There are no Officers of Paradigm who are former partners of RSM Australia.
Auditor’s independence declaration
The Auditor’s Independence Declaration as required under section 307C of the Corporations Act 2001 is set out on page
20 of the financial report.
RSM Australia Partners will continue in office in accordance with section 327 of the Corporations Act 2001. Pursuant to
section 324 DAB of the Corporations Act 2001, the Board on 11 April 2019, following a recommendation from Audit and
Risk Committee, approved that Jason Croall, a partner of RSM Australia Partners may continue to play a significant role in
the audit of the Consolidated Entity for a further 2 years until the financial year ended 30 June 2021.
Reasons for the extension include continuity of knowledge and experience that Jason has accumulated over the years, as
well as, key relationships formed during this period, is considered a material benefit to maintaining the quality of audit work
for a further period covering the two financial years ending 30 June 2020 and 2021.
The Board is satisfied that the extension of the auditor rotation period is consistent with maintaining the quality of the audit
and would not give rise to conflict of interest situation. RSM Australia Partners has agreed to extend the above extension.
12
PARADIGM BIOPHARMACEUTICALS LIMITED
R E M U N E R A T I O N R E P O R T
AUDITED REMUNERATION REPORT
This Remuneration Report outlines the Director and Executive Remuneration arrangements of Paradigm in accordance with
the requirements of the Corporations Act 2001 and the Corporations Regulations 2001.
For the purposes of this report, Key Management Personnel of Paradigm are defined as those persons having authority and
responsibility for planning, directing and controlling the major activities of Paradigm, directly or indirectly, including any
Director (whether executive or otherwise) of Paradigm. Paradigm does not presently employ any Executives, other than the
Executive Director.
KEY MANAGEMENT PERSONNEL
The following were Key Management Personnel of Paradigm at any time during the year and unless otherwise indicated
were Key Management Personnel for the entire year:
Name
Position held
Date Appointed
Graeme Kaufman
Paul Rennie
Christopher Fullerton
John Gaffney
Chairman & Non-Executive Director
Managing & Executive Director
Non-Executive Director
Non-Executive Director
2 May 2014
2 May 2014
30 September 2014
30 September 2014
REMUNERATION COMMITTEE
The Nomination and Remuneration Committee proposes candidates for Director appointment for the Board's consideration,
reviews the fees payable to both Executive and Non-Executive Directors and reviews and advises the Board in relation to
Chief Executive Officer succession planning. The Nomination and Remuneration Committee has the authority to consult
any independent professional adviser it considers appropriate to assist it in meeting its responsibilities.
The Nomination and Remuneration Committee is a committee of the Board and is established in accordance with the
authority provided in Paradigm’s constitution.
The Board is responsible to shareholders for ensuring that Paradigm:
has coherent remuneration policies and practices which are observed, and which enable it to attract and retain
Executives and Directors who will create value for shareholders;
fairly and responsibly rewards executives having regard to the performance of Paradigm, the performance of the
Executive and the general pay environment;
provides disclosure in relation to Paradigm's remuneration policies to enable investors to understand the costs and
benefits of those policies and the link between remuneration paid to Directors and key Executives and corporate
performance; and
complies with the provisions of the ASX Listing Rules and the Corporations Act 2001.
PRINCIPLES OF REMUNERATION
The primary purpose of the Nomination and Remuneration Committee is to support and advise the Board in fulfilling its
responsibilities to shareholders in ensuring that the Board is appropriately remunerated, structured and comprised of
individuals who are best able to discharge the responsibilities of Directors by:
assessing the size, composition, diversity and skills required by the Board to enable it to fulfil its responsibilities to
shareholders, having regard to Paradigm’s current and proposed scope of activities;
assessing the extent to which the required knowledge, experience and skills are represented on the Board;
establishing processes for the identification of suitable candidates for appointment to the Board;
overseeing succession planning for the Board and CEO;
establishing processes for the review of the performance of individual Directors and the Board as a whole;
assessing the terms of appointment and remuneration arrangements for Non-Executive Directors; and
assessment and reporting to the Board
Remuneration structure
In accordance with best practice Corporate Governance, the structure of Non-Executive Directors’ Remuneration is clearly
distinguished from that of Executives.
13
PARADIGM BIOPHARMACEUTICALS LIMITED
R E M U N E R A T I O N R E P O R T ( C O N T ’ D )
Non-Executive Director Remuneration
The Constitution and the ASX Listing Rules specify that the aggregate remuneration of Non-Executive Directors shall be
determined from time to time by a general meeting. Remuneration of Non-Executive Directors is determined in maximum
aggregate by the shareholders and is allocated by the Board on the recommendation of the Remuneration Committee. The
Remuneration Committee will take independent advice in respect to Directors' fees on an as needed basis.
There is no separate payment made for attendance at Board committee meetings or for other attendances to Consolidated
Entity or Board activities.
Directors are not required to hold shares in Paradigm as part of their appointment.
There is to be no plan to provide remuneration, reward or other benefits to Non-Executive Directors upon the cessation of
them holding office as a Director.
Executive remuneration
Executive Directors receive no extra remuneration for their service on the Board beyond their executive salary package.
Fixed compensation
Fixed compensation consists of base compensation, as well as employer contributions to superannuation funds.
Compensation levels are reviewed annually by the remuneration committee through a process that considers individual,
segment and overall performance of Paradigm.
Short-term incentives
Executive Key Management Personnel may receive short-term incentives.
Long-term incentives
Share-based compensation - Options granted to Directors and key management personnel
Paradigm has a long-term incentive plan being the Employee Share Plan (ESP). Refer to Note 12 for further information on
the Plan. The shares issued under the ESP are considered to be options under the Australian Accounting standards.
Issue of shares
Details of shares issued to Directors and other Key Management Personnel as part of the ESP compensation:
Name
Date
Shares
Issue price
Fair value
of
options
$
Graeme Kaufman
Paul Rennie
29 May 2015
1,200,000
$0.35
$0.208
249,600
29 May 2015
600,000
$0.35
$0.208
124,800
30 November 2016
140,000
$0.33
$0.268
37,553
13 November 2017
210,000
$0.63
$0.198
41,496
26 November 2018
300,000
$1.15
$0.623
186,963
Christopher Fullerton
29 May 2015
600,000
$0.35
$0.208
124,800
John Gaffney
29 May 2015
600,000
$0.35
$0.208
124,800
14
PARADIGM BIOPHARMACEUTICALS LIMITED
R E M U N E R A T I O N R E P O R T ( C O N T ’ D )
Movement in shares
The movement during the reporting period in the number of ordinary shares in Paradigm Biopharmaceuticals Limited held
directly, indirectly or beneficially by each Director and Key Management Personnel, including their related entities is as
follows:
Held at year Purchases
Disposals
Issued via Held at year
opening
ESP
end
Directors & Key Management
Persons
Graeme Kaufman
2,074,250
-
Paul Rennie
22,599,543
480,392
Christopher Fullerton
736,000
224,000
John Gaffney
703,250
-
-
-
-
-
-
2,074,250
300,000
23,379,935
-
-
960,000
703,250
EMPLOYMENT AGREEMENTS
The Board has reviewed the remuneration package for the Chief Executive Officer on 26 June 2019. The Remuneration and
other terms of employment for the Chief Executive Officer is formalised in a service agreement. Details of this agreement
are as follows: -
Name:
Title:
Agreement commenced:
Term of agreement:
Details:
Paul Rennie
Managing Director and Chief Executive Officer
7 November 2017
3 years
Base annual package *, Short-term incentives ** and discretionary share based Long-
term incentives ***, subject to annual performance review, 6-month termination notice
by either party, 3-12-month non-solicitation clause after termination depending on the
area. Paradigm may terminate the agreement with cause in certain circumstances such
as gross misconduct.
* Base annual package for financial year 2019/20 - $462,000 per annum plus statutory
Superannuation, to be reviewed annually by the Nomination and Remuneration
Committee
** Short-term incentives paid as a cash bonus to award for financial year 2018/19 –
25% of base ($105,000)
*** Long-term incentives via invitation to participate in Paradigm’s Employee Share
Plan. 300,000 Ordinary Shares was granted as at 26 November 2018 at an exercise
price of $1.15 for the performance for the 2018 financial year. This issue was funded
by a limited recourse loan from Paradigm.
15
PARADIGM BIOPHARMACEUTICALS LIMITED
R E M U N E R A T I O N R E P O R T ( C O N T ’ D )
REMUNERATION OF KEY MANAGEMENT PERSONNEL
Details of the nature and amount of each major element of the remuneration of each Key Management Personnel of Paradigm for the year ended 30 June 2019 are:
Short-term
Post-
employment
Long-term
Share-based
payments
Salary & fees
Cash Bonus
Superannuation
benefits
Long service
leave
Options
Total
Proportion of
remuneration
performance
related
Value of
options as
proportion of
remuneration
$
$
$
$
$
$
%
%
Directors & Key Management
Personnel
Non-Executive
Graeme Kaufman
Christopher Fullerton
John Gaffney
Executive
Paul Rennie
110,000
55,000
55,000
-
-
-
10,450
5,225
5,225
420,000
105,000
49,875
Total
2019
640,000
105,000
70,775
* This figure includes accruals for year ended 30 June 2019 to be ratified at AGM in November 2019.
-
-
-
-
-
-
-
-
120,450
60,225
60,225
0.0%
0.0%
0.0%
0.00%
0.00%
0.00%
492,513
1,067,388
9.84%
46.14%
492,513
1,308,288
8.03%
37.65%
16
PARADIGM BIOPHARMACEUTICALS LIMITED
R E M U N E R A T I O N R E P O R T ( C O N T ’ D )
REMUNERATION OF KEY MANAGEMENT PERSONNEL (cont’d)
Details of the nature and amount of each major element of the remuneration of each Key Management Personnel of Paradigm for the year ended 30 June 2018 are:
Short-term
Post-
employment
Long-term
Share-based
payments
Salary & fees
Cash Bonus
Superannuation
benefits
Long service
leave
Options
Total
Proportion of
remuneration
performance
related
Value of
options as
proportion of
remuneration
$
$
$
$
$
$
%
%
Directors & Key Management
Personnel
Non-Executive
Graeme Kaufman
Christopher Fullerton
John Gaffney
Executive
Paul Rennie
110,000
55,000
55,000
-
-
-
10,450
5,225
5,225
380,000
105,000
46,075
Total
2018
600,000
105,000
66,975
-
-
-
-
-
-
-
-
120,450
60,225
60,225
0.0%
0.0%
0.0%
0.00%
0.00%
0.00%
41,496
572,571
18.34%
7.25%
41,496
813,471
12.91%
5.10%
17
PARADIGM BIOPHARMACEUTICALS LIMITED
R E M U N E R A T I O N R E P O R T ( C O N T ’ D )
REMUNERATION OF KEY MANAGEMENT PERSONNEL (cont’d)
The proportion of remuneration linked to performance and the fixed proportion are as follows:
Name
Non-Executive
Graeme Kaufman
Christopher Fullerton
John Gaffney
Executive:
Paul Rennie
Fixed remuneration
At risk - STI
At risk - LTI
2019
2018
2019
2018
2019
2018
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
-
-
-
-
-
-
-
-
-
-
-
-
44.02%
74.71%
9.84%
18.34%
46.14%
7.25%
Cash bonuses are dependent on meeting defined performance measures. The amount of the bonus is determined having regard to the satisfaction of performance measures. The
maximum bonus values are established at the start of each financial year and amounts payable are determined in the final month of the financial year by the Nomination and
Remuneration Committee.
The proportion of the cash bonus paid/payable or forfeited is as follows:
Name
Non-Executive
Graeme Kaufman
Christopher Fullerton
John Gaffney
Executive:
Paul Rennie
Cash bonus paid/payable
Cash bonus forfeited
2019
2018
2019
2018
-
-
-
-
-
-
100%
100%
-
-
-
-
-
-
-
-
18
PARADIGM BIOPHARMACEUTICALS LIMITED
R E M U N E R A T I O N R E P O R T ( C O N T ’ D )
REMUNERATION OF KEY MANAGEMENT PERSONNEL (cont’d)
Additional information
The earnings of Paradigm for the five years to 30 June 2019 are summarised below:-
Income
Profit after income tax
3,245,628
2,736,400
1,848,924
1,394,161
7,331
(15,627,544)
(6,190,232)
(4,275,446)
(2,924,425)
(1,565,305)
2019
$
2018
$
2017
$
2016
$
2015
$
The factors that are considered to affect total shareholders return (TSR) are summarised below:
Share price at financial year end ($)
Total dividends declared (cents per share)
Basic earnings per share (cents per share)
2019
1.40
-
(10.93)
2018
0.65
-
(5.46)
2017
0.29
-
(4.42)
2016
0.35
-
(3.60)
2015
-
-
(4.68)
This is the end of the audited Remuneration Report.
Dated at Melbourne, Victoria this 30th day of August 2019.
Signed in accordance with a resolution of the Directors:
Graeme Kaufman
Chairman
19
RSM Australia Partners
Level 21, 55 Collins Street Melbourne VIC 3000
PO Box 248 Collins Street West VIC 8007
T +61 (0) 3 9286 8000
F +61 (0) 3 9286 8199
www.rsm.com.au
AUDITOR’S INDEPENDENCE DECLARATION
As lead auditor for the audit of the financial report of Paradigm Biopharmaceuticals Limited for the year ended 30
June 2019, I declare that, to the best of my knowledge and belief, there have been no contraventions of:
(i)
(ii)
the auditor independence requirements of the Corporations Act 2001 in relation to the audit; and
any applicable code of professional conduct in relation to the audit.
RSM AUSTRALIA PARTNERS
J S CROALL
Partner
Dated: 30 August 2019
Melbourne, Victoria
THE POWER OF BEING UNDERSTOOD
AUDIT | TAX | CONSULTING
20
RSM Australia Partners is a member of the RSM network and trades as RSM. RSM is the trading name used by the members of the RSM network. Each member of the
RSM network is an independent accounting and consulting firm which practices in its own right. The RSM network is not itself a separate legal entity in any jurisdiction.
RSM Australia Partners ABN 36 965 185 036
Liability limited by a scheme approved under Professional Standards Legislation
PARADIGM BIOPHARMACEUTICALS LIMITED
C O N S O L I D A T E D S T A T E M E N T O F P R O F I T O R L O S S A N D
O T H E R C O M P R E H E N S I V E I N C O M E
f o r t h e y e a r e n d e d 3 0 J u n e 2 0 1 9
Other income
Research and development expenses
Employee expenses
General and administration expenses
Impairment loss
Period from Period from
1-Jul-18 to
30-Jun-19
1-Jul-17 to
30-Jun-18
Notes
$
$
2
3
3,245,628
2,736,400
(7,896,708)
(6,594,575)
(2,575,983)
(1,048,197)
(1,471,497)
(1,283,860)
(6,928,984)
-
Loss before income tax
(15,627,544)
(6,190,232)
Income tax expense / (benefit)
-
-
Loss for the year
Other comprehensive income
(15,627,544)
(6,190,232)
-
-
Total comprehensive income attributable to members of the consolidated entity
(15,627,544)
(6,190,232)
Earnings per share (cents)
Basic and diluted earnings per share
16
(10.93) cents
(5.46) cents
The consolidated statement of profit or loss and other comprehensive income is to be read in conjunction with the
accompanying notes.
21
PARADIGM BIOPHARMACEUTICALS LIMITED
C O N S O L I D A T E D S T A T E M E N T O F F I N A N C I A L P O S I T I O N
a s a t 3 0 J u n e 2 0 1 9
Notes
2019
$
2018
$
ASSETS
Current assets
Cash and cash equivalents
Trade and other receivables
Prepaid expenses
Financial assets held at amortised cost
Total current assets
Non-current assets
Intangible assets
Plant and equipment
Total non-current assets
Total assets
LIABILITIES
Current liabilities
Trade and other payables
Employee benefits
Total current liabilities
Net assets
EQUITY
Issued capital
Share based payments reserve
Accumulated losses
Total equity
4
5
6
17
7
8
72,336,173
2,445,630
3,532,227
2,734,779
137,113
91,973
6,500,000
-
82,505,513
5,272,382
2,981,359
9,910,242
24,029
8,542
3,005,388
9,918,784
85,510,901
15,191,166
9
10
2,315,992
1,066,726
388,591
260,371
2,704,583
1,327,097
82,806,318
13,864,069
11
12
13
109,468,292
26,940,674
4,072,844
2,030,669
(30,734,818)
(15,107,274)
82,806,318
13,864,069
The consolidated statement of financial position is to be read in conjunction with the accompanying notes.
22
PARADIGM BIOPHARMACEUTICALS LIMITED
C O N S O L I D A T E D S T A T E M E N T O F C A S H F L O W S
f o r t h e y e a r e n d e d 3 0 J u n e 2 0 1 9
Period from
1-Jul-18 to
Period from
1-Jul-17 to
30-Jun-19
30-Jun-18
$
$
Cash flows from operating activities
Research and development tax incentive received
2,318,718
1,773,582
Payments to suppliers and employees (Inclusive of GST)
(8,773,072)
(7,839,364)
Interest received
89,259
52,321
Net cash outflow from operating activities
(6,365,095)
(6,013,461)
Cash flows from investing activities
Payments for intangible assets
Payments for plant and equipment
Payments for financial assets held at amortised cost
(4,198)
(12,291)
(17,781)
(3,053)
(6,500,000)
-
Net cash outflow from investing activities
(6,521,979)
(15,344)
Cash flows from financing activities
Proceeds from the issue of share capital
Proceeds from exercise of share options
Payments of share issue costs
86,962,482
5,550,000
1,084,854
955,358
(5,269,719)
(621,735)
Net cash inflow from financing activities
82,777,617
5,883,623
Net increase/ (decrease) in cash and cash equivalents
69,890,543
(145,182)
Cash at the beginning of the financial period
2,445,630
2,590,812
Cash at the end of the financial period
72,336,173
2,445,630
The consolidated statement of cash flows is to be read in conjunction with the accompanying notes.
23
PARADIGM BIOPHARMACEUTICALS LIMITED
C O N S O L I D A T E D S T A T E M E N T O F C H A N G E S I N E Q U I T Y
f o r t h e y e a r e n d e d 3 0 J u n e 2 0 1 9
Issued
Capital
$
Share
Option
Reserve
$
Accumulated
Losses
$
Total
$
Balance at 30 June 2017
21,057,052
1,249,910
(8,917,042)
13,389,920
Loss for the period
Shares issued (Note 11)
Costs in relation to shares issued
Fair value of shares issued to eligible employees under the plan
Fair values of options issued to third party under the share-based payment arrangement
-
6,505,357
(621,735)
-
-
-
-
-
362,955
417,804
(6,190,232)
-
-
-
-
(6,190,232)
6,505,357
(621,735)
362,955
417,804
Balance at 30 June 2018
26,940,674
2,030,669
(15,107,274)
13,864,069
Loss for the period
Shares issued (Note 11)
Costs in relation to shares issued
Fair value of shares issued to eligible employees under the plan
Fair values of options issued to third party under the share-based payment arrangement
Exercise of unlisted options
-
86,962,483
(5,519,719)
-
-
1,084,854
-
-
-
1,728,963
313,212
-
(15,627,544)
-
-
-
-
-
(15,627,544)
86,962,483
(5,519,719)
1,728,963
313,212
1,084,854
Balance at 30 June 2019
109,468,292
4,072,844
(30,734,818)
82,806,318
The consolidated statement of changes in equity is to be read in conjunction with the accompanying note
24
PARADIGM BIOPHARMACEUTICALS LIMITED
N O T E S T O T H E C O N S O L I D A T E D F I N A N C I A L S T A T E M E N T S
f o r t h e y e a r e n d e d 3 0 J u n e 2 0 1 9
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The principal accounting policies adopted in the preparation of the Financial Statements are set out below. These policies
have been consistently applied to all the years presented, unless otherwise stated.
New, revised or amending Accounting Standards and Interpretations adopted
The Consolidated Entity has adopted all of the new, revised or amending Accounting Standards and Interpretations issued
by the Australian Accounting Standards Board (‘AASB’) that are mandatory for the current reporting period.
Any new, revised or amending Accounting Standards or Interpretations that are not yet mandatory have not been early
adopted.
The following Accounting Standards and Interpretations are most relevant to the Consolidated Entity:
AASB 9 Financial Instruments
The Consolidated Entity has adopted AASB 9 from 1 July 2018. The standard introduced new classification and
measurement models for financial assets. A financial asset shall be measured at amortised cost if it is held within a business
model whose objective is to hold assets in order to collect contractual cash flows which arise on specified dates and that are
solely principal and interest. A debt investment shall be measured at fair value through other comprehensive income if it is
held within a business model whose objective is to both hold assets in order to collect contractual cash flows which arise on
specified dates that are solely principal and interest as well as selling the asset on the basis of its fair value. All other financial
assets are classified and measured at fair value through profit or loss unless the entity makes an irrevocable election on
initial recognition to present gains and losses on equity instruments (that are not held-for-trading or contingent consideration
recognised in a business combination) in other comprehensive income (‘OCI’). Despite these requirements, a financial asset
may be irrevocably designated as measured at fair value through profit or loss to reduce the effect of, or eliminate, an
accounting mismatch. For financial liabilities designated at fair value through profit or loss, the standard requires the portion
of the change in fair value that relates to the entity’s own credit risk to be presented in OCI (unless it would create an
accounting mismatch). New simpler hedge accounting requirements are intended to more closely align the accounting
treatment with the risk management activities of the entity. New impairment requirements use an ‘expected credit loss’
(‘ECL’) model to recognise an allowance. Impairment is measured using a 12-month ECL method unless the credit risk on
a financial instrument has increased significantly since initial recognition in which case the lifetime ECL method is adopted.
For receivables, a simplified approach to measuring expected credit losses using a lifetime expected loss allowance is
available.
The impact is immaterial as per Note 17 there are minimal financial instruments in the accounts.
AASB 15 Revenue from Contracts with Customers
The Consolidated Entity has adopted AASB 15 from 1 July 2018. The standard provides a single comprehensive model for
revenue recognition. The core principle of the standard is that an entity shall recognise revenue to depict the transfer of
promised goods or services to customers at an amount that reflects the consideration to which the entity expects to be
entitled in exchange for those goods or services. The standard introduced a new contract-based revenue recognition model
with a measurement approach that is based on an allocation of the transaction price. This is described further in the
accounting policies below. Credit risk is presented separately as an expense rather than adjusted against revenue. Contracts
with customers are presented in an entity’s statement of financial position as a contract liability, a contract asset, or a
receivable, depending on the relationship between the entity’s performance and the customer’s payment. Customer
acquisition costs and costs to fulfil a contract can, subject to certain criteria, be capitalised as an asset and amortised over
the contract period.
The impact of its adoption is minimal as the Consolidated Entity is still in the research phase and is yet to generate revenue.
Currently revenue is minimal and relates to mainly interest and R&D rebates.
(a) Reporting entity
Paradigm Biopharmaceuticals Limited (the “Consolidated Entity”) is a company incorporated and domiciled in Australia.
Paradigm Biopharmaceuticals Limited is a company limited by shares which are publicly traded on the Australian Securities
Exchange from 19 August 2015. The consolidated financial report of the Consolidated Entity for the year ended 30 June
2019 comprises the company and controlled entities (together referred to as the “Consolidated Entity”).
The nature of the operations and principal activities of the Consolidated Entity are described in the Directors’ Report.
For the purposes of preparing the Financial Statements the Consolidated Entity is a for-profit entity.
25
PARADIGM BIOPHARMACEUTICALS LIMITED
N O T E S T O T H E C O N S O L I D A T E D F I N A N C I A L S T A T E M E N T S
f o r t h e y e a r e n d e d 3 0 J u n e 2 0 1 9
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont’d)
(b) Basis of preparation
Statement of Compliance
This financial report is a general purpose financial report prepared in accordance with the Australian Accounting Standards
(“AASs”) (including Australian Accounting Interpretations) adopted by the Australian Accounting Standards Board and the
Corporations Act 2001. This Consolidated Financial Report complies with the International Financial Reporting Standards
(”IFRSs”) and interpretations adopted by the International Accounting Standards Board (IASB).
Basis of measurement
Historical cost convention
The Financial Statements have been prepared under the historical cost convention, except for, where applicable, the
revaluation of available-for-sale financial assets, financial assets and liabilities at fair value through profit or loss, investment
properties, certain classes of plant and equipment and derivative financial instruments.
Critical accounting estimates
The preparation of the Financial Statements requires the use of certain critical accounting estimates. It also requires
management to exercise its judgement in the process of applying the Consolidated Entity’s accounting policies. The areas
involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the
Financial Statements, are disclosed in note 1 (c).
Significant accounting policies
The accounting policies set out below have been applied consistently by the Consolidated Entity to all periods presented in
these Financial Statements.
New and amended standards adopted by the entity.
The Consolidated Entity has reviewed and applied all new accounting standards and amendments applicable for the first
time in their annual reporting period commencing 1 July 2018 and determined that there was no material impact on the
Consolidated Entity’s Financial Statements in the current reporting year.
(c) Significant accounting estimates, assumptions and judgements
The preparation of the Financial Statements requires management to make judgements, estimates and assumptions that
affect the reported amounts in the Financial Statements. Management continually evaluates its judgements and estimates
in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements and estimates
on historical experience and on other various factors it believes to be reasonable under the circumstances. The resulting
accounting judgements and estimates will seldom equal the related actual results. The judgements, estimates and
assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities
(refer to the respective notes) within the next financial year are discussed below.
Share-based payment transactions
The Consolidated Entity measures the cost of equity-settled transactions with employees by reference to the fair value of
the equity instruments at the date at which they are granted. The fair value is determined by using either the Binomial or
Black-Scholes model taking into account the terms and conditions upon which the instruments were granted. The accounting
estimates and assumptions relating to equity-settled share-based payments would have no impact on the carrying amounts
of assets and liabilities within the next annual reporting period but may impact profit or loss and equity.
Estimation of useful lives of assets
The Consolidated Entity determines the estimated useful lives and related depreciation and amortisation charges for its plant
and equipment and finite life intangible assets. The useful lives could change significantly as a result of technical innovations
or some other event. The depreciation and amortisation charge will increase where the useful lives are less than previously
estimated lives, or technically obsolete or non-strategic assets that have been abandoned or sold will be written off or written
down.
26
PARADIGM BIOPHARMACEUTICALS LIMITED
N O T E S T O T H E C O N S O L I D A T E D F I N A N C I A L S T A T E M E N T S
f o r t h e y e a r e n d e d 3 0 J u n e 2 0 1 9
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont’d)
(c) Significant accounting estimates, assumptions and judgements (cont’d)
Impairment of non-financial assets other than goodwill and other indefinite life intangible assets
The Consolidated Entity assesses impairment of non-financial assets other than goodwill and other indefinite life intangible
assets at each reporting date by evaluating conditions specific to the Consolidated Entity and to the particular asset that may
lead to impairment. If an impairment trigger exists, the recoverable amount of the asset is determined. This involves fair value
less costs of disposal or value-in-use calculations, which incorporate a number of key estimates and assumptions.
Employee benefits provision
As discussed in note 1, the liability for employee benefits expected to be settled more than 12 months from the reporting
date are recognised and measured at the present value of the estimated future cash flows to be made in respect of all
employees at the reporting date. In determining the present value of the liability, estimates of attrition rates and pay increases
through promotion and inflation have been considered.
(d) Summary of Significant Accounting Policies
(i)
Basis of consolidation
Parent entity
In accordance with the Corporations Act 2001, these Financial Statements present the results of the Consolidated Entity
only. Supplementary information about the parent entity is disclosed in note 19.
Subsidiaries
The consolidated Financial Statements comprise those of the Consolidated Entity, and the entities it controlled at the end of,
or during, the financial year. The balances and effects of transactions between entities in the Consolidated Entity included
in the Financial Statements have been eliminated. Where an entity either began or ceased to be controlled during the year,
the results are included only from the date control commenced or up to the date control ceased.
Subsidiaries are entities controlled by the Consolidated Entity. Control exists when the Consolidated Entity is exposed to or
has rights to variable returns from its involvement with the entity and has the ability to affect those returns through its power
to direct the activities of the entity. The Financial Statements of subsidiaries are included in the consolidated Financial
Statements from the date control is transferred to the Consolidated Entity until the date that control ceases.
Transactions eliminated on consolidation
Intra-company balances and all gains and losses or income and expenses arising from intra-company transactions are
eliminated in preparing the consolidated Financial Statements.
(ii)
Cash and cash equivalents
Cash and cash equivalents in the statement of financial position comprise cash at bank and in hand and short-term deposits
with an original maturity of three months or less that are readily convertible to known amounts of cash and which are subject
to an insignificant risk of changes in value.
For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and cash equivalents as defined
above but also include as a component of cash and cash equivalents bank overdrafts (if any), which are included as
borrowings on the statement of financial position.
(iii)
Trade and other receivables
Trade receivables are initially recognised at fair value and subsequently measured at amortised cost using the effective
interest method, less any provision for impairment. Trade receivables are generally due for settlement within 30 days.
Collectability of trade receivables is reviewed on an ongoing basis. Debts which are known to be uncollectable are written
off by reducing the carrying amount directly. A provision for impairment of trade receivables is raised when there is objective
evidence that the Consolidated Entity will not be able to collect all amounts due according to the original terms of the
receivables. Significant financial difficulties of the debtor, probability that the debtor will enter bankruptcy or financial
reorganisation and default or delinquency in payments (more than 60 days overdue) are considered indicators that the trade
receivable may be impaired. The amount of the impairment allowance is the difference between the asset's carrying amount
and the present value of estimated future cash flows, discounted at the original effective interest rate. Cash flows relating to
short-term receivables are not discounted if the effect of discounting is immaterial.
Other receivables are recognised at amortised cost, less any provision for impairment.
27
PARADIGM BIOPHARMACEUTICALS LIMITED
N O T E S T O T H E C O N S O L I D A T E D F I N A N C I A L S T A T E M E N T S
f o r t h e y e a r e n d e d 3 0 J u n e 2 0 1 9
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont’d)
(iv)
Investments
Investments are initially measured at cost. Transaction costs are included as part of the initial measurement. They are
subsequently measured at either amortised cost or fair value depending on their classification. Classification is determined
based on the purpose of the acquisition and subsequent reclassification to other categories is restricted.
(v)
Intangible assets
Intangible assets acquired as part of a business combination, other than goodwill, are initially measured at their fair value at
the date of the acquisition. Intangible assets acquired separately are initially recognised at cost. Indefinite life intangible
assets are not amortised and are subsequently measured at cost less any impairment. Finite life intangible assets are
subsequently measured at cost less amortisation and any impairment. The gains or losses recognised in profit or loss arising
from the derecognition of intangible assets are measured as the difference between net disposal proceeds and the carrying
amount of the intangible asset. The method and useful lives of finite life intangible assets are reviewed annually. Changes
in the expected pattern of consumption or useful life are accounted for prospectively by changing the amortisation method
or period.
(a) Patents and trademarks
Patents have a finite useful life and are carried at cost less accumulated amortisation and impairment losses once the patents
are considered held ready for use. Intellectual property and licences are amortised on a systematic basis matched to the
future economic benefits over the useful life of the project once the patents are considered held ready for use.
Significant costs associated with trademarks are deferred and amortised on a straight-line basis over the period of their
expected benefit, being their finite life of 10 years.
(b) Research and development
Expenditure during the research phase of a project is recognised as an expense when incurred. Development costs are
capitalised only when technical feasibility studies identify that the project will deliver future economic benefits and these
benefits can be measured reliably.
(vi)
Impairment
At the end of each reporting period, the Consolidated Entity assesses whether there is any indication that an asset may be
impaired. The assessment will include considering external sources of information and internal sources of information. If
such an indication exists, an impairment test is carried out on the asset by comparing the recoverable amount of the asset,
being the higher of the asset’s fair value less costs to sell and value-in-use, to the asset’s carrying value. Any excess of the
asset’s carrying value over its recoverable amount is expensed to the statement of comprehensive income.
Where it is not possible to estimate the recoverable amount of an individual asset, the Consolidated Entity estimates the
recoverable amount of the cash-generating unit to which the asset belongs.
Impairment testing is performed annually for goodwill and intangible assets with indefinite lives.
In assessing value-in-use, the estimated future cash flows are discounted to their present value using a pre-tax discount
rate that reflects current market assessments of the time value of the money and risks specific to the asset. In determining
fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified,
an appropriate valuation model is used. These calculations are corroborated by valuation multiples, quoted share prices for
publicly traded companies or other available fair value indicators.
The Consolidated Entity bases its impairment calculation on detailed budgets and forecast calculations, which are prepared
separately for each of the Consolidated Entity’s projects to which the individual assets are allocated. These budgets and
forecast calculations generally cover a period of five years.
Impairment losses of continuing operations are recognised in the statement of profit or loss in expense categories consistent
with the function of the impaired asset.
(vii)
Plant and equipment
Plant and equipment is stated at historical cost less accumulated depreciation and impairment. Historical cost includes
expenditure that is directly attributable to the acquisition of the items.
Depreciation is calculated on a straight-line basis to write off the net cost of each item of plant and equipment over their
expected useful lives of 2-15 years.
28
PARADIGM BIOPHARMACEUTICALS LIMITED
N O T E S T O T H E C O N S O L I D A T E D F I N A N C I A L S T A T E M E N T S
f o r t h e y e a r e n d e d 3 0 J u n e 2 0 1 9
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont’d)
(vii) Plant and equipment (cont’d)
The residual values, useful lives and depreciation methods are reviewed, and adjusted if appropriate, at each reporting date.
Leasehold improvements and plant and equipment under lease are depreciated over the unexpired period of the lease or the
estimated useful life of the assets, whichever is shorter.
An item of plant and equipment is derecognised upon disposal or when there is no future economic benefit to the Consolidated
Entity. Gains and losses between the carrying amount and the disposal proceeds are taken to profit or loss. Any revaluation
surplus reserve relating to the item disposed of is transferred directly to retained profits.
(viii)
Trade and other payables
Trade and other payables represent the liability outstanding at the end of the reporting period for goods and services received
by the entity during the reporting period which remain unpaid. The balance is recognised as a current liability with the amounts
normally paid within the requisite terms specified by the supplier.
(ix)
Share capital
Ordinary and preference shares are classified as equity.
Any incremental costs directly attributable to the issue of new shares or options are recognised in equity as a deduction, net
of tax, from the proceeds.
(x)
Provisions
Provisions are recognised when the Consolidated Entity has a present (legal or constructive) obligation as a result of a past
event, it is probable the Consolidated Entity will be required to settle the obligation, and a reliable estimate can be made of
the amount of the obligation. The amount recognised as a provision is the best estimate of the consideration required to
settle the present obligation at the reporting date, taking into account the risks and uncertainties surrounding the obligation.
If the time value of money is material, provisions are discounted using a current pre-tax rate specific to the liability. The
increase in the provision resulting from the passage of time is recognised as a finance cost.
(xi) Revenue
Interest income
Interest income is recognised on a time proportion basis using the effective interest rate method.
Other revenue
Other revenue is recognised when it is received or when the right to receive payment is established.
Government grants
Grants that compensate the Consolidated Entity for expenditures incurred are recognised in profit or loss on a systematic
basis in the periods in which the expenditures are recognised. R&D tax offset receivables will be recognised in profit before
tax (in EBIT) over the periods necessary to match the benefit of the credit with the costs for which it is intended to
compensate. Such periods will depend on whether the R&D costs are capitalised or expensed as incurred.
(xii) Employee benefits
Wages and salaries, cash bonus, annual leave and long service leave
Provision is made for benefits accruing to employees in respect of wages and salaries, annual leave and long service leave
when it is probable that settlement will be required, and they are capable of being measured reliably. Provisions made in
respect of employee benefits are measured based on an assessment of the existing benefits to determine the appropriate
classification under the definition of short-term and long-term benefits, placing emphasis on when the benefit is expected to
be settled.
Short-term benefits provisions that are expected to be settled within 12 months are measured at their nominal values using
the remuneration rate expected to apply at the time of settlement.
29
PARADIGM BIOPHARMACEUTICALS LIMITED
N O T E S T O T H E C O N S O L I D A T E D F I N A N C I A L S T A T E M E N T S
f o r t h e y e a r e n d e d 3 0 J u n e 2 0 1 9
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont’d)
(xii) Employee benefits (cont’d)
Long term benefits provisions that are not expected to be settled within 12 months and are measured as the present value
of the estimated future cash outflows to be made by the Consolidated Entity in respect of services provided by employees
up to reporting date. Consideration is given to the expected future wage and salary levels, experience of employee
departures and periods of service. Expected future payments are discounted using market yields at the reporting date to
estimate the future cash flows at a pre-tax rate that reflects current market assessments of the time value of money.
Regardless of the expected timing of settlement, provisions made in respect of employee benefits are classified as a current
liability unless there is an unconditional right to defer the settlement of the liability for at least 12 months after the reporting
date, in which case it would be classified as a non-current liability. Provisions made for annual leave and unconditional long
service leave are classified as a current liability where the employee has a present entitlement to the benefit. Provisions for
conditional long service are classified as non-current liability.
Share-based payments
The Consolidated Entity operates an incentive scheme to provide these benefits, known as the Paradigm Biopharmaceuticals
Limited Employee Share Plan (“ESP”) approved on 22 October 2014. Issues of shares to employees with limited recourse
loans under the ESP are share based payments in the form of options.
The fair value of options granted under the ESP is recognised as an employee benefit expense with a corresponding increase
in equity. The fair value is measured at grant date and recognised over the period during which the employees become
unconditionally entitled to the options. The fair value at grant date is determined using a binomial pricing model that takes
into account the exercise price, the term of the option, the vesting and performance criteria, the share price at grant date and
expected price volatility of the underlying share, the expected dividend yield and the risk-free interest rate for the term of the
limited recourse loan. In valuing share-based payment transactions, no account is taken of any non-market performance
conditions.
The Consolidated Entity provides benefits to employees (including Directors) of the Consolidated Entity in the form of share-
based payment transactions, whereby employees render services in exchange for shares or rights over shares.
The cost of share-based payment transactions is recognised, together with a corresponding increase in equity, over the
period in which the performance conditions are fulfilled, ending on the date on which the relevant employees become fully
entitled to the award (‘vesting date’). The cumulative expense recognised for equity-settled transactions at each reporting
date until vesting date reflects (i) the extent to which the vesting period has expired and (ii) the number of awards that, in the
opinion of the Directors of the Consolidated Entity, will ultimately vest. This opinion is formed based on the best available
information at balance date. No adjustment is made for the likelihood of market performance conditions being met as the
effect of these conditions is included in the determination of fair value at grant date.
No expense is recognised for awards that do not ultimately vest, except for awards where vesting is conditional upon a
market condition.
Where the terms of an equity-settled award are modified, as a minimum an expense is recognised as if the terms had not
been modified. In addition, an expense is recognised for any increase in the value of the transaction as a result of the
modification, as measured at the date of modification.
Where an equity-settled award is cancelled, it is treated as if it had vested on the date of cancellation, and any expense not
yet recognised for the award is recognised immediately. However, if a new award is substituted for the cancelled award, and
designated as a replacement award on the date that it is granted, the cancelled and new award are treated as if they were
a modification of the original award, as described in the previous paragraph.
(xiii) Income tax
The income tax expense or benefit for the period is the tax payable on that period's taxable income based on the applicable
income tax rate for each jurisdiction, adjusted by the changes in deferred tax assets and liabilities attributable to temporary
differences, unused tax losses and the adjustment recognised for prior periods, where applicable.
Deferred tax assets and liabilities are recognised for temporary differences at the tax rates expected to be applied when the
assets are recovered or liabilities are settled, based on those tax rates that are enacted or substantively enacted, except for:
when the deferred income tax asset or liability arises from the initial recognition of goodwill or an asset or liability in
a transaction that is not a business combination and that, at the time of the transaction, affects neither the
accounting nor taxable profits; or
when the taxable temporary difference is associated with interests in subsidiaries, associates or joint ventures,
and the timing of the reversal can be controlled and it is probable that the temporary difference will not reverse in
the foreseeable future.
30
PARADIGM BIOPHARMACEUTICALS LIMITED
N O T E S T O T H E C O N S O L I D A T E D F I N A N C I A L S T A T E M E N T S
f o r t h e y e a r e n d e d 3 0 J u n e 2 0 1 9
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont’d)
(xiii) Income tax (cont’d)
Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probable that
future taxable amounts will be available to utilise those temporary differences and losses.
The carrying amount of recognised and unrecognised deferred tax assets are reviewed at each reporting date. Deferred tax
assets recognised are reduced to the extent that it is no longer probable that future taxable profits will be available for the
carrying amount to be recovered. Previously unrecognised deferred tax assets are recognised to the extent that it is probable
that there are future taxable profits available to recover the asset.
Deferred tax assets and liabilities are offset only where there is a legally enforceable right to offset current tax assets against
current tax liabilities and deferred tax assets against deferred tax liabilities; and they relate to the same taxable authority on
either the same taxable entity or different taxable entities which intend to settle simultaneously.
The Consolidated Entity and its wholly-owned Australian resident entities are part of a tax-consolidated entity. As a
consequence, all members of the tax-consolidated entity are taxed as a single entity. The head entity within the tax-
consolidated entity is Paradigm Biopharmaceuticals Limited.
Current tax expense/income, deferred tax liabilities and deferred tax assets arising from temporary differences of the
members of the tax-consolidated entity are recognised in the separate Financial Statements of the members of the tax-
consolidated entity using the ‘separate taxpayer within Consolidated Entity’ approach by reference to the carrying amount of
assets and liabilities in the separate Financial Statements of each entity and the tax values applying under tax consolidation.
Any current tax liabilities (or assets) and deferred tax assets arising from unused tax losses of the subsidiaries are assumed
by the head entity in the tax-consolidated entity. Any difference between these amounts is recognised by the Consolidated
Entity as an equity contribution or distribution.
Any subsequent period adjustments to deferred tax assets arising from unused tax losses as a result of revised assessments
of the probability of recoverability is recognised by the head entity only.
Assets or liabilities arising under tax funding agreements with the tax consolidated entities are recognised as amounts
receivable from or payable to other entities in the tax consolidated group. The tax funding arrangement ensures that the
intercompany charge equals the current tax liability or benefit of each tax consolidated group member, resulting in neither a
contribution by the head entity to the subsidiaries nor a distribution by the subsidiaries to the head entity.
(xiv) Current and non-current classification
Assets and liabilities are presented in the statement of financial position based on current and non-current classification.
An asset is classified as current when: it is either expected to be realised or intended to be sold or consumed in the
Consolidated Entity's normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within
12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used
to settle a liability for at least 12 months after the reporting period. All other assets are classified as non-current.
A liability is classified as current when: it is either expected to be settled in the Consolidated Entity’s normal operating cycle;
it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting period; or there is no
unconditional right to defer the settlement of the liability for at least 12 months after the reporting period. All other liabilities
are classified as non-current.
(xv) Goods and Services Tax
Revenues, expenses and assets are recognised net of the amount of goods and services tax (GST), except where the
amount of GST incurred is not recoverable from the Australian Tax Office (ATO). In these circumstances the GST is
recognised as part of the cost of acquisition of the asset or as part of an item of the expense.
Receivables and payables are stated with the amount of GST included.
The net amount of GST recoverable from, or payable to, the ATO is included as a current asset or liability in the statement
of financial position.
Cash flows are included in the statement of cash flows at their nominal value inclusive of GST.
31
PARADIGM BIOPHARMACEUTICALS LIMITED
N O T E S T O T H E C O N S O L I D A T E D F I N A N C I A L S T A T E M E N T S
f o r t h e y e a r e n d e d 3 0 J u n e 2 0 1 9
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont’d)
(xvi) Earnings per share
The Consolidated Entity presents basic and, when applicable, diluted earnings per share (“EPS”) data for its ordinary shares.
Basic EPS is calculated by dividing the profit or loss attributable to the ordinary shareholders of the Consolidated Entity by
the weighted average number of ordinary shares outstanding during the period.
Diluted EPS is calculated by adjusting basic earnings for the impact of the after-tax effect of costs associated with dilutive
ordinary shares and the weighted average number of additional ordinary shares that would be outstanding assuming the
conversion of all dilutive potential ordinary shares. The dilutive effect, if any, of outstanding options is reflected as additional
share dilution in the computation of earnings per share.
(xvii) Fair value measurement
When an asset or liability, financial or non-financial, is measured at fair value for recognition or disclosure purposes, the fair
value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction
between market participants at the measurement date; and assumes that the transaction will take place either: in the principal
market; or in the absence of a principal market, in the most advantageous market.
Fair value is measured using the assumptions that market participants would use when pricing the asset or liability, assuming
they act in their economic best interests. For non-financial assets, the fair value measurement is based on its highest and
best use. Valuation techniques that are appropriate in the circumstances and for which sufficient data are available to
measure fair value, are used, maximising the use of relevant observable inputs and minimising the use of unobservable
inputs.
Assets and liabilities measured at fair value are classified, into three levels, using a fair value hierarchy that reflects the
significance of the inputs used in making the measurements. Classifications are reviewed at each reporting date and
transfers between levels are determined based on a reassessment of the lowest level of input that is significant to the fair
value measurement.
For recurring and non-recurring fair value measurements, external valuers may be used when internal expertise is either not
available or when the valuation is deemed to be significant. External valuers are selected based on market knowledge and
reputation. Where there is a significant change in fair value of an asset or liability from one period to another, an analysis is
undertaken, which includes a verification of the major inputs applied in the latest valuation and a comparison, where
applicable, with external sources of data.
New standards and interpretations not yet effective or early adopted
Australian Accounting Standards and Interpretations that have recently been issued or amended but are not yet mandatory,
have not been early adopted by the Consolidated Entity for the annual reporting period ended 30 June 2019. The
Consolidated Entity's assessment of the impact of these new or amended Accounting Standards and Interpretations, most
relevant to the Consolidated Entity, are set out below:
AASB 16 Leases
This standard is applicable to annual reporting periods beginning on or after 1 January 2019. The standard replaces AASB
117 'Leases' and for lessees will eliminate the classifications of operating leases and finance leases. Subject to exceptions,
a 'right-of-use' asset will be capitalised in the statement of financial position, measured at the present value of the unavoidable
future lease payments to be made over the lease term. The exceptions relate to short-term leases of 12 months or less and
leases of low-value assets (such as personal computers and small office furniture) where an accounting policy choice exists
whereby either a 'right-of-use' asset is recognised or lease payments are expensed to profit or loss as incurred. A liability
corresponding to the capitalised lease will also be recognised, adjusted for lease prepayments, lease incentives received,
initial direct costs incurred and an estimate of any future restoration, removal or dismantling costs. Straight-line operating
lease expense recognition will be replaced with a depreciation charge for the leased asset (included in operating costs) and
an interest expense on the recognised lease liability (included in finance costs). The Consolidated Entity adopts this standard
from 1 July 2019 but there is no impact as there are no operating leases in place as at 30 June 2019.
32
PARADIGM BIOPHARMACEUTICALS LIMITED
N O T E S T O T H E C O N S O L I D A T E D F I N A N C I A L S T A T E M E N T S
f o r t h e y e a r e n d e d 3 0 J u n e 2 0 1 9
2. OTHER INCOME
R&D tax incentive
Interest received
3. EMPLOYEE EXPENSES
2019
$
2018
$
2,983,918
261,710
2,682,501
53,899
3,245,628
2,736,400
Wages, salaries and self-employed contractors expenses
Performance bonus
Defined contribution superannuation expenses
Increase in liability for employee benefits expenses
Non-executive directors fees
Fair values of shares issued/to be issued to eligible employees under the ESP
Workcover
Payroll tax
254,000
18,900
46,826
91,228
220,000
1,728,963
2,894
213,172
230,000
17,500
44,412
111,346
220,000
362,955
3,612
58,372
2,575,983
1,048,197
4. CASH AND CASH EQUIVALENTS
Cash at bank and in hand
72,336,173
2,445,630
5. TRADE AND OTHER RECEIVABLES
GST receivable
Interest receivable
R&D tax incentive receivable
6. PREPAID EXPENSES
Prepaid insurance
Other prepaid expenses
7. INTANGIBLE ASSETS
Patents
Less: Accumulated amortisation and impairment losses
33
72,336,173
2,445,630
10,497
174,029
50,700
1,578
3,347,701
2,682,501
3,532,227
2,734,779
16,247
120,866
11,111
80,862
137,113
91,973
9,922,163
(6,940,804)
9,917,122
(6,880)
2,981,359
9,910,242
PARADIGM BIOPHARMACEUTICALS LIMITED
N O T E S T O T H E C O N S O L I D A T E D F I N A N C I A L S T A T E M E N T S
f o r t h e y e a r e n d e d 3 0 J u n e 2 0 1 9
7. INTANGIBLE ASSETS (cont’d)
Reconciliation
Carrying amount at the beginning of the period
Additions during the period
Disposals
Amortisation expense
Impairment loss
2019
$
2018
$
9,910,242
4,198
-
(4,097)
(6,928,984)
9,904,830
12,292
-
(6,880)
-
Balance at the end of the financial year
2,981,359
9,910,242
The Consolidated Entity performed its annual impairment test in June 2019. There was a particular focus on the respiratory
asset due to the unexpected outcome of Phase 2a Allergic Rhinitis clinical trial which failed to meet its primary clinical
endpoints in June 2017. The Consolidated Entity remains committed to its respiratory asset. The Allergic Rhinitis Phase 2
study could be repeated or the Allergic Rhinitis program may be terminated in preference to its Asthma or Chronic Obstructive
Pulmonary Disease (COPD) programs depending on the findings of the potential reasons for the lack of translation of the
preclinical Allergic Rhinitis results into the Phase 2 human clinical trial.
Respiratory patent
The respiratory patent covers the use of PPS for treating Allergic Rhinitis, Allergic Asthma and COPD. The Respiratory
patent is now granted in Australia, New Zealand, China, Canada and Europe.
The recoverable amount of the respiratory patent as at 30 June 2019, has been determined based on a value-in-use
calculation using a 1-year cash flow projection from financial budgets approved by senior management and extrapolated for
a further 4 years using a 10% growth rate. The after-tax discount rate applied to cash flow projections is 11.25%. It was
concluded that the fair value less costs of disposal exceed the value-in-use. As a result of this analysis, management has
recognized an impairment charge.
IL-1RA Peptide (anti-inflammatory/autoimmune patent) and Xosoma
The Board has taken the strategic decision to focus all of the Consolidated Entity’s resources on accelerating the
development of iPPS in the key indications of osteoarthritis, viral arthritis and mucopolysaccharidosis. Building on strong
results in the respective clinical programs, these indications provide the most compelling opportunity for early revenue
generation and significant commercial partnerships. The focus on creating shareholder value through concentrating on fast
progression of these core iPPS clinical assets has led to formally discontinue clinical development of the non-core, non-iPPS
product candidates (IL-1RA Peptide and Xosoma), at least for the time being. As a result, while the Consolidated Entity
continues to retain the rights to the program, management has taken the prudent decision to write off the value.
Key assumptions used in value-in-use calculations and sensitivity to changes in assumptions
The calculation of value-in-use for both respiratory and anti-inflammatory/autoimmune patents is most sensitive to the
following assumptions:
Discount rate
Growth rate
Comparable deals for drug treatments
The discount rate of 11.25% after-tax reflects the Consolidated Entity’s estimated cost of capital based on the risk-free rate,
market risk premium and the volatility of the share price relative to market movements. If the discount rate is increased to
20%, the recoverable amount of the respiratory patents are decreased by 28.65%. These recoverable amounts comfortably
remain above their carrying values.
Management believes the estimated 10% growth rate for expenses is prudent.
The comparable deals used in the value-in-use calculation are conservative based on the current market space. If the
comparable deals are increased by 10%, the recoverable amount of the respiratory patents are increased by 16.24%
34
PARADIGM BIOPHARMACEUTICALS LIMITED
N O T E S T O T H E C O N S O L I D A T E D F I N A N C I A L S T A T E M E N T S
f o r t h e y e a r e n d e d 3 0 J u n e 2 0 1 9
8. PLANT AND EQUIPMENT
Computer equipment
Less: Accumulated depreciation
Reconciliation
Carrying amount at the beginning of the period
Additions during the period
Disposals
Depreciation expense
2019
$
2018
$
40,282
(22,618)
20,544
(20,159)
17,663
385
385
19,737
-
(2,459)
4,753
1,786
-
(6,154)
Balance at the end of the financial year
17,663
385
Clinical trial equipment
Less: Accumulated depreciation
Reconciliation
Carrying amount at the beginning of the period
Additions during the period
Disposals
Depreciation expense
9,419
(6,807)
9,419
(5,283)
2,613
4,136
4,136
-
-
(1,523)
4,901
1,266
-
(2,031)
Balance at the end of the financial year
2,613
4,136
Office equipment
Less: Accumulated depreciation
Reconciliation
Carrying amount at the beginning of the period
Additions during the period
Disposals
Depreciation expense
Balance at the end of the financial year
4,390
(637)
3,753
4,021
-
-
(268)
3,753
24,029
4,390
(369)
4,021
4,308
-
-
(287)
4,021
8,542
35
PARADIGM BIOPHARMACEUTICALS LIMITED
N O T E S T O T H E C O N S O L I D A T E D F I N A N C I A L S T A T E M E N T S
f o r t h e y e a r e n d e d 3 0 J u n e 2 0 1 9
9. TRADE AND OTHER PAYABLES
Trade and other creditors
Shareholder loans
10. EMPLOYEE BENEFITS
Annual leave and on-costs
2019
$
2018
$
2,279,403
36,589
1,030,137
36,589
2,315,992
1,066,726
388,591
260,371
388,591
260,371
The current provision for employee benefits includes all unconditional entitlements where employees have completed the
required period of service and also those where employees are entitled to pro-rate payments in certain circumstances. The
entire amount is presented as current since the Consolidated Entity does not have an unconditional right to defer settlement.
11. ISSUED CAPITAL
2019
Number of
Shares
2018
Number of
Shares
2019
$
2018
$
Ordinary shares Fully paid
192,207,761
123,963,792
109,468,292
26,940,674
The following movements in issued capital occurred during the year:
2019
2018
Number of
Shares
$
Number of
Shares
$
Ordinary Shares
Balance as at the beginning of the period
123,963,792
26,940,674
101,925,220
21,057,052
Ordinary shares issued
65,476,945
86,962,483
18,499,999
5,550,000
Ordinary shares issue costs
-
(5,519,719)
-
(621,735)
Shares issued under ESP
300,000
-
1,110,000
-
Exercise of unlisted options
2,467,024
1,084,854
2,428,573
955,357
Balance as at the end of the period
192,207,761
109,468,292
123,963,792
26,940,674
36
PARADIGM BIOPHARMACEUTICALS LIMITED
N O T E S T O T H E C O N S O L I D A T E D F I N A N C I A L S T A T E M E N T S
f o r t h e y e a r e n d e d 3 0 J u n e 2 0 1 9
11. ISSUED CAPITAL (cont’d)
Ordinary shares
Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the Consolidated Entity
in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and
the Consolidated Entity does not have a limited amount of authorised capital.
On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each
share shall have one vote.
Capital risk management
The Consolidated Entity's objectives when managing capital is to safeguard its ability to continue as a going concern, so that
it can provide returns for shareholders and benefits for other stakeholders and to maintain an optimum capital structure to
reduce the cost of capital.
Capital is regarded as total equity, as recognised in the statement of financial position, plus net debt. Net debt is calculated
as total borrowings less cash and cash equivalents.
In order to maintain or adjust the capital structure, the Consolidated Entity may adjust the number of dividends paid to
shareholders, return capital to shareholders, issue new shares or sell assets to reduce debt.
The Consolidated Entity would look to raise capital when an opportunity to invest in a business or company was seen as
value adding relative to the current Consolidated Entity's share price at the time of the investment. The Consolidated Entity
is not actively pursuing additional investments in the short-term as it continues to integrate and grow its existing businesses
in order to maximise synergies.
The Consolidated Entity is subject to certain financing arrangements covenants and meeting these is given priority in all
capital risk management decisions. There have been no events of default on the financing arrangements during the financial
year.
The capital risk management policy remains unchanged from the 30 June 2018 Annual Report.
12. SHARE BASED PAYMENT RESERVE
Balance as at the beginning of the period
Fair values of shares issued to eligible employees under the ESP
Fair values of options issued to third party under the share-based payment
arrangement
2019
$
2018
$
2,030,669
1,728,963
1,249,910
362,955
313,212
417,804
4,072,844
2,030,669
Once approved by the Board, monies are loaned by the Consolidated Entity interest free and on a non-recourse basis to
participants to finance the purchase of shares in the company. The ESP shares are registered in the name of participants
but are subject to a restriction on disposal for a period of five years (from date of issue) and for further periods whilst they
remain financed. On cessation of employment, the entitlement to any shares held for less than three years is pro-rated.
On 26 November 2018, 300,000 shares were issued at a price of $1.15 per share.
On 26 June 2019, a further invitation of ESP shares valued at $1,542,000 based on 2019 performance were approved to be
issued upon the shareholders’ approval at the AGM. The total number of shares to be issued is fixed with reference to the
share price at the time of the AGM. These shares were valued using the Binomial Hoadley model with an exercise price and
share price of $1.285, volatility of 82% and risk-free rate of 1.07%.
The shares issued under the ESP are treated as options for accounting purposes. They do not expire, and vest immediately
on grant date.Fair values at loan date are determined using a Binomial Hoadley pricing model that takes into account the
issue price, the term of the loan, the share price at loan date and expected price volatility of the underlying share, the
expected dividend yield and the risk-free interest rate for the term of the loan.
37
PARADIGM BIOPHARMACEUTICALS LIMITED
N O T E S T O T H E C O N S O L I D A T E D F I N A N C I A L S T A T E M E N T S
f o r t h e y e a r e n d e d 3 0 J u n e 2 0 1 9
12. SHARE OPTIONS RESERVE (cont’d)
The weighted average share price during the financial year was $1.14. Throughout the period a number of share options
were issued in the period in relation to services rendered by third parties. These predominantly relate to services provided
around capital raising.
Set out below are summaries of options granted under the Employee Share plan:
2019
Grant date
Expiry date
Exercise
price
Balance at
the start of
the year
Granted
Exercised
Balance at
the end of
the year
26/11/2018
26/11/2023
$1.15
5,505,000
300,000
5,505,000
300,000
-
-
5,805,000
5,805,000
2018
Grant date
Expiry date
Exercise
price
Balance at
the start of
the year
Granted
Exercised
Balance at
the end of
the year
30/06/2018
30/06/2023
$0.57
-
900,000
13/11/2017
13/11/2022
$0.63
4,395,000
210,000
4,395,000
1,110,000
-
-
-
900,000
4,605,000
5,505,000
For the options granted during the current financial year, the valuation model inputs used to determine the fair value at
the grant date, are as follows:
Grant date
Expiry date
Share price
at
grant date
Exercise
price
Expected
volatility
Dividend
yield
Fair value
at
grant date
26/11/2018
26/11/2023
$1.15
$1.15
85.00%
0.00%
$0.62
In addition, the Consolidated Entity has the following unlisted options as at 30 June 2019: -
(i)
(ii)
(iii)
(iv)
(v)
2,000,000 unlisted options exercisable at $0.40 each on or before 19 January 2020 in accordance with existing
corporate services mandate; the weighted average remaining contractual life of options outstanding at the end
of the financial year was 0.56 year;
2,000,000 unlisted options exercisable at $0.45 each on or before 27 September 2020 in accordance with
existing corporate services mandate; the weighted average remaining contractual life of options outstanding at
the end of the financial year was 1.25 years;
192,500 unlisted options exercisable at $0.312 each on or before 15 November 2020 in accordance with
existing corporate services mandate; the weighted average remaining contractual life of options outstanding at
the end of the financial year was 1.38 years;
1,000,000 unlisted options exercisable at $0.45 each on or before 07 May 2021 in accordance with existing
corporate services mandate the weighted average remaining contractual life of options outstanding at the end
of the financial year was 1.85 years; and
1,000,000 unlisted options exercisable at $0.65 each on or before 18 May 2021 in accordance with existing
corporate services mandate; the weighted average remaining contractual life of options outstanding at the end
of the financial year was 1.88 years.
38
PARADIGM BIOPHARMACEUTICALS LIMITED
N O T E S T O T H E C O N S O L I D A T E D F I N A N C I A L S T A T E M E N T S
f o r t h e y e a r e n d e d 3 0 J u n e 2 0 1 9
12. SHARE OPTIONS RESERVE (cont’d)
Set out below are summaries of options granted to external companies for services rendered in the period:
2019
Grant date
Expiry date
Exercise
price
Balance at
the start of
the year
Granted
Exercised
Balance at
the end of
the year
18/05/2018
18/05/2021
$0.65
1,000,000
07/05/2018
07/05/2021
$0.45
1,000,000
16/11/2017
15/11/2020
$0.31
350,000
27/09/2017
27/09/2020
$0.45
2,000,000
19/01/2017
19/01/2020
$0.40
2,000,000
07/08/2015
07/08/2018
$0.375
952,382
07/08/2015
07/08/2018
$0.50
1,357,142
-
-
-
-
-
-
-
-
-
1,000,000
1,000,000
(157,500)
192,500
-
-
2,000,000
2,000,000
(952,382)
-
(1,357,142)
-
8,659,524
-
(2,467,024)
6,192,500
2018
Grant date
Expiry date
18/05/2018
18/05/2021
07/05/2018
07/05/2021
16/11/2017
15/11/2020
27/09/2017
27/09/2020
Exercise
price
Balance at
the start of
the year
Granted
Exercised
Balance at
the end of
the year
$0.65
$0.45
$0.31
$0.45
-
-
-
-
1,000,000
1,000,000
350,000
2,000,000
-
-
-
-
-
1,000,000
1,000,000
350,000
2,000,000
2,000,000
(2,071,430)
952,382
(357,143)
1,357,142
19/01/2017
19/01/2020
$0.40
2,000,000
07/08/2015
07/08/2018
$0.375
3,023,812
07/08/2015
07/08/2018
$0.50
1,714,285
-
-
-
6,738,097
4,350,000
(2,428,573)
8,659,524
39
PARADIGM BIOPHARMACEUTICALS LIMITED
N O T E S T O T H E C O N S O L I D A T E D F I N A N C I A L S T A T E M E N T S
f o r t h e y e a r e n d e d 3 0 J u n e 2 0 1 9
13. ACCUMULATED LOSSES
Balance as at the beginning of the period
Loss for the accounting period
2019
$
2018
$
(15,107,274)
(15,627,544)
(8,917,042)
(6,190,232)
(30,734,818)
(15,107,274)
14. COMMITMENTS
The Consolidated Entity had no capital commitments as at 30 June 2019 and 30 June 2018.
15. CONTINGENCIES
During the financial year, the Consolidated Entity has received a claim for professional fees from its latest capital raise. The
Consolidated Entity strongly disputes that the fees are owing and will vigorously defend its position.
The Consolidated Entity had no contingent liabilities as at 30 June 2018.
2019
$
2018
$
16. EARNINGS PER SHARE
Net loss for the year attributable to ordinary shareholders
(15,627,544)
(6,190,232)
Weighted average number of ordinary shares used in calculating basic
earnings per share
Adjustments for calculation of diluted earnings per share:
Options over ordinary shares
Number
Number
143,042,225
113,453,460
6,192,500
8,659,524
Weighted average number of ordinary shares used in calculating diluted
earnings per share
149,234,725
122,112,984
Basic earnings per share
Diluted earnings per share
Cents
Cents
(10.93)
(10.93)
(5.46)
(5.46)
40
PARADIGM BIOPHARMACEUTICALS LIMITED
N O T E S T O T H E C O N S O L I D A T E D F I N A N C I A L S T A T E M E N T S
f o r t h e y e a r e n d e d 3 0 J u n e 2 0 1 9
17. FINANCIAL INSTRUMENTS DISCLOSURE
The Consolidated Entity’s financial instruments consist mainly of deposits with banks, short-term investments, accounts
receivable and accounts payable.
The totals for each category of financial instruments, measured in accordance with AASB 139 as detailed in the accounting
policies of these Financial Statements, are as follows:
Financial assets
Current
Cash and cash equivalents
Trade and other receivables
Term deposits
Financial liabilities
Current
2019
$
2018
$
72,336,173
2,445,630
3,532,227
2,734,779
6,500,000
-
82,368,400
5,180,409
Trade and other payables at amortised cost
2,315,992
1,066,726
Financial risk management objectives
The Consolidated Entity's activities expose it to a variety of financial risks: market risk (including foreign currency risk), credit
risk and liquidity risk. The Consolidated Entity's overall risk management program focuses on the unpredictability of financial
markets and seeks to minimise potential adverse effects on the financial performance of the Consolidated Entity. The
Consolidated Entity uses different methods to measure different types of risk to which it is exposed. These methods include
sensitivity analysis in the case of interest rate, foreign exchange and other price risks, ageing analysis for credit risk.
Risk management is carried out by senior finance executives ('finance') under policies approved by the Board of Directors
('the Board'). These policies include identification and analysis of the risk exposure of the Consolidated Entity and
appropriate procedures, controls and risk limits. Finance identifies, evaluates and hedges financial risks within the
Consolidated Entity's operating units. Finance reports to the Board on a monthly basis.
Market risk
Market risk is the risk that changes in market prices, such as foreign exchange rates, interest rates and equity prices will
affect the Consolidated Entity’s income and expenses or the value of its holdings of financial instruments. The objective of
market risk management is to manage and control market risk exposures within acceptable parameters, while optimising
the return.
Equity price risk
The Consolidated Entity is currently not subject to equity price risk movement.
Interest rate risk
Interest rate risk is the risk that the value of a financial instrument or cash flows associated with the instrument will fluctuate
due to changes in market interest rates. Interest rate risk arises from fluctuations in interest bearing financial assets and
liabilities that the Consolidated Entity uses. Interest bearing assets comprise cash and cash equivalents which are
considered to be short-term liquid assets and investment decisions are governed by the monetary policy.
During the year, the Consolidated Entity had no variable rate interest bearing liability.
It is the Consolidated Entity's policy to settle trade payables within the credit terms allowed and therefore not incur interest
on overdue balances
41
PARADIGM BIOPHARMACEUTICALS LIMITED
N O T E S T O T H E C O N S O L I D A T E D F I N A N C I A L S T A T E M E N T S
f o r t h e y e a r e n d e d 3 0 J u n e 2 0 1 9
17. FINANCIAL INSTRUMENTS DISCLOSURE (cont’d)
Credit risk
Credit risk is the risk of financial loss to the Consolidated Entity if a customer or counterparty to a financial instrument fails
to meet its contractual obligations and arises principally from the Consolidated Entity’s receivables from customers and
investment securities.
The Consolidated Entity does not presently have customers and consequently does not have credit exposure to outstanding
receivables. Trade and other receivables represent GST refundable from the Australian Taxation Office and R&D Tax
incentive claims. Trade and other receivables are neither past due nor impaired.
Liquidity risk
Liquidity risk is the risk that the Consolidated Entity will not be able to meet its financial obligations as they fall due. The
Consolidated Entity’s approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient
liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses
or risking damage to the Consolidated Entity’s reputation.
The Consolidated Entity’s objective is to maintain a balance between continuity of funding and flexibility. The Consolidated
Entity’s exposure to financial obligations relating to corporate administration and projects expenditure, are subject to
budgeting and reporting controls, to ensure that such obligations do not exceed cash held and known cash inflows for a
period of at least 1 year.
Fair value of financial assets and liabilities
The fair value of cash and cash equivalents and non-interest bearing financial assets and financial liabilities of the
Consolidated Entity is equal to their carrying value.
Foreign currency risk
The Consolidated Entity’s exposure to currency risk is minimal at this stage of the operations.
Commodity price risk
The Consolidated Entity’s exposure to price risk is minimal at this stage of the operations.
18. RELATED PARTIES
Parent entity
The Parent Entity is Paradigm Biopharmaceuticals Limited.
Controlled entities
The controlled entities are Paradigm Health Sciences Pty Ltd, Xosoma Pty Ltd and C4M Pharmaceuticals Pty Ltd.
In the Financial Statements of the Consolidated Entity investments in subsidiaries are measured at cost. All entity interests
held are fully paid ordinary shares or units.
The consolidated Financial Statements incorporate the assets, liabilities and results of the following wholly-owned
subsidiaries in accordance with the accounting policy described in note 1:
Name
Paradigm Health Sciences Pty Ltd
Xosoma Pty Ltd
C4M Pharmaceuticals Pty Ltd
Subsidiaries
Ownership interest
Principal
place of
business
Australia
Australia
Australia
2019
2018
%
100.00%
100.00%
100.00%
%
100.00%
100.00%
100.00%
An inter-company loan exists between Paradigm Biopharmaceuticals Limited (parent) and Paradigm Health Sciences
(subsidiary) of amounts owing to Paradigm Biopharmaceuticals Limited (parent) $334,061 (2018: $334,061).
42
PARADIGM BIOPHARMACEUTICALS LIMITED
N O T E S T O T H E C O N S O L I D A T E D F I N A N C I A L S T A T E M E N T S
f o r t h e y e a r e n d e d 3 0 J u n e 2 0 1 9
18. RELATED PARTIES (cont’d)
Receivable from and payable to related parties
There were no transactions that took place to or from related parties at the current and previous reporting date.
19. PARENT ENTITY DISCLOSURES
Set out below is the supplementary information about the parent entity:
Statement of profit or loss and other comprehensive income
2019
$
2018
$
Loss after income tax
(15,627,544)
(6,190,232)
Statement of financial position
Total current assets
Total Assets
Total current liabilities
Total Liabilities
Total Equity
82,839,565
5,606,434
85,720,805
15,401,070
2,667,994
1,290,508
2,667,994
1,290,508
81,692,995
14,110,561
There are no guarantees entered into by the parent entity in relation to the debts of its subsidiaries.
Contingent liabilities
During the financial year, the parent entity has received a claim for professional fees from its latest capital raise. The parent
entity strongly disputes that the fees are owing and will vigorously defend its position.
The parent entity had no contingent liabilities as at 30 June 2018.
Capital commitments
The parent entity had no capital commitments as at 30 June 2019 and 30 June 2018.
Significant accounting policies
The accounting policies of the parent entity are consistent with those of the Consolidated Entity.
20. RECONCILIATION OF CASH FLOWS PROVIDED BY OPERATING ACTIVITIES
Loss for the year
(15,627,544)
(6,190,232)
Depreciation and amortisation
Impairment loss
Share-based payment
Change in operating assets and liabilities
(Increase)/ decrease in receivables
(Increase)/ decrease in prepayments
Increase /(decrease) in trade creditors and accruals
8,348
6,928,984
2,042,175
(797,448)
(45,140)
1,125,530
15,352
-
780,759
(920,167)
(70,980)
371,807
Net cash used in operating activities
(6,365,095)
(6,013,461)
43
PARADIGM BIOPHARMACEUTICALS LIMITED
N O T E S T O T H E C O N S O L I D A T E D F I N A N C I A L S T A T E M E N T S
f o r t h e y e a r e n d e d 3 0 J u n e 2 0 1 9
2019
$
2018
$
21. NON CASH INVESTING AND FINANCING ACTIVITIES
Shares issued/to be issued under employee share plan
options issued to third party under the share-based payment arrangement
1,728,963
313,212
321,459
109,515
2,042,175
430,974
22. EVENTS SUBSEQUENT TO REPORTING DATE
No other matters or circumstances have arisen since balance date which have impacted or are likely to impact the
Consolidated Entity’s operations, results and state of affairs in future financial years.
23. KEY MANAGEMENT PERSONNEL REMUNERATION DISCLOSURES
The aggregate remuneration made to directors and other members of key management personnel of the Consolidated Entity
is set out below:
Short-term employee benefits
Post-employment benefits
Share-based payments
24. AUDITOR REMUNERATION NOTE
745,000
70,775
492,513
705,000
66,975
41,496
1,308,288
813,471
During the financial year the following fees were paid or payable for services provided by RSM Australia Partners, the
auditor of the company
Audit services - RSM Australia Partners
Audit or review of the financial statements
Other services - RSM Australia Partners
Preparation of the tax return and other tax matters
R&D Tax incentive claim
62,672
56,000
62,672
50,500
10,000
59,212
3,700
75,000
69,212
78,700
131,884
134,700
44
PARADIGM BIOPHARMACEUTICALS LIMITED
D I R E C T O R S ’ D E C L A R A T I O N
In the opinion of the Directors of Paradigm Biopharmaceuticals Limited and Controlled Entities:
(a)
the Financial Statements and notes thereto and the Remuneration Report contained in the Directors’ Report are in
accordance with the Corporations Act 2001, including:
(i)
(ii)
giving a true and fair view of the Consolidated Entity’s financial position as at 30 June 2019 and their
performance for the financial year ended on that date; and
complying with Australian Accounting Standards (including the Australian Accounting Interpretations) and the
Corporations Regulations 2001; and
(b)
the financial report also complies with International Financial Reporting Standards;
(c)
there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due
and payable.
The Directors have been given the declarations required by Section 295A of the Corporations Act for the financial year
ending 30 June 2019.
Signed in accordance with a resolution of the Directors made pursuant to section 295(5)(a) of the Corporations Act 2001.
On behalf of the Directors
___________________________
Graeme Kaufman
Chairman
Dated at Melbourne, Victoria this 30th day of August 2019.
45
INDEPENDENT AUDITOR’S REPORT
To the Members of Paradigm Biopharmaceuticals Ltd
RSM Australia Partners
Level 21, 55 Collins Street Melbourne VIC 3000
PO Box 248 Collins Street West VIC 8007
T +61 (0) 3 9286 8000
F +61 (0) 3 9286 8199
www.rsm.com.au
Opinion
We have audited the financial report of Paradigm Biopharmaceuticals Ltd (the Company), and its subsidiaries (the
Consolidated Entity), which comprises the consolidated statement of financial position as at 30 June 2019, the
consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes
in equity and the consolidated statement of cash flows for the year then ended, and notes to the financial
statements, including a summary of significant accounting policies, and the directors' declaration.
In our opinion the accompanying financial report of the consolidated entity is in accordance with the Corporations
Act 2001, including:
(i) giving a true and fair view of the Consolidated Entity's financial position as at 30 June 2019 and of its
financial performance for the year then ended; and
(ii) complying with Australian Accounting Standards and the Corporations Regulations 2001.
Basis for Opinion
We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those
standards are further described in the Auditor's Responsibilities for the Audit of the Financial Report section of
our report. We are independent of the Consolidated Entity in accordance with the auditor independence
requirements of the Corporations Act 2001 and the ethical requirements of the Accounting Professional and
Ethical Standards Board's APES 110 Code of Ethics for Professional Accountants (the Code) that are relevant to
our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance
with the Code.
We confirm that the independence declaration required by the Corporations Act 2001, which has been given to
the directors of the Company, would be in the same terms if given to the directors as at the time of this auditor's
report.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our
opinion.
Key Audit Matters
Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of
the financial report of the current period. These matters were addressed in the context of our audit of the financial
report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.
THE POWER OF BEING UNDERSTOOD
AUDIT | TAX | CONSULTING
46
RSM Australia Partners is a member of the RSM network and trades as RSM. RSM is the trading name used by the members of the RSM network. Each member of the
RSM network is an independent accounting and consulting firm which practices in its own right. The RSM network is not itself a separate legal entity in any jurisdiction.
RSM Australia Partners ABN 36 965 185 036
Liability limited by a scheme approved under Professional Standards Legislation
Key Audit Matter
How our audit addressed this matter
Impairment of Intangible Assets
Refer to Note 7 in the financial statements
The Consolidated Entity has identifiable intangible
assets totalling $2.9m relating to Development costs
for various ongoing projects in the development of
numerous biopharmaceutical drugs acquired as part
of various business acquisitions. These are subject to
an annual impairment test, as they are not yet
available for use.
We identified this area as a Key Audit Matter due to
the size of the intangible assets balance and the
complexity in building a financial model to assess
whether there exists any possible impairment.
For the year ended 30 June 2019 management have
performed an
the
intangibles balance by:
impairment assessment over
Assessing for each project the success to date in
line with agreed milestones including any clinical
trial data; and other statistical test results;
Assessing additional funding to be spent on the
project and the plan going forward including the
use of the patent for other uses; and
Calculating the value in use for the Respiratory
project using a discounted cash flow model. The
model used cash flows (revenues and expenses)
for each project for 5 years, with a terminal growth
rate applied to the 5th year. These cash flows
were then discounted to net present value using
the Group’s weighted average cost of capital
(WACC).
Our audit procedures in relation to management’s
impairment assessment included:
Reviewing announcements to date in relation to
the details of current developments and results of
testing for each project;
Consideration of the market capitalisation of the
company compared to the total net assets;
Reviewing historical milestones in line with current
progress including future projected spending on
each project to assess the viability and continuity
of each of these.
Reviewing the value in use calculation, including
challenging
key
assumptions, including the cash flow projections,
exchange rates, discount rates, and sensitivities
used; and
reasonableness
the
of
Checking the mathematical accuracy of the cash
to
flow model, and
supporting evidence, such as approved budgets
and considering the reasonableness of these
budgets.
input data
reconciling
Other Information
The directors are responsible for the other information. The other information comprises the information included
in the Consolidated Entity's annual report for the year ended 30 June 2019, but does not include the financial
report and the auditor's report thereon.
Our opinion on the financial report does not cover the other information and accordingly we do not express any
form of assurance conclusion thereon.
In connection with our audit of the financial report, our responsibility is to read the other information and, in doing
so, consider whether the other information is materially inconsistent with the financial report or our knowledge
obtained in the audit or otherwise appears to be materially misstated.
If, based on the work we have performed, we conclude that there is a material misstatement of this other
information, we are required to report that fact. We have nothing to report in this regard.
47
Responsibilities of the Directors for the Financial Report
The directors of the Company are responsible for the preparation of the financial report that gives a true and fair
view in accordance with Australian Accounting Standards and the Corporations Act 2001 and for such internal
control as the directors determine is necessary to enable the preparation of the financial report that gives a true
and fair view and is free from material misstatement, whether due to fraud or error.
In preparing the financial report, the directors are responsible for assessing the ability of the Consolidated Entity's
to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going
concern basis of accounting unless the directors either intend to liquidate the Consolidated Entity's or to cease
operations, or have no realistic alternative but to do so.
Auditor's Responsibilities for the Audit of the Financial Report
Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from
material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion.
Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance
with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements
can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably
be expected to influence the economic decisions of users taken on the basis of this financial report.
A further description of our responsibilities for the audit of the financial report is located at the Auditing and
Assurance Standards Board website at: www.auasb.gov.au/auditors_responsibilities/ar2.pdf. This description
forms part of our auditor's report.
Report on the Remuneration Report
Opinion on the Remuneration Report
We have audited the Remuneration Report included in the directors' report for the year ended 30 June 2019.
In our opinion, the Remuneration Report of Paradigm Biopharmaceuticals Ltd, for the year ended 30 June 2019,
complies with section 300A of the Corporations Act 2001.
Responsibilities
The directors of the Company are responsible for the preparation and presentation of the Remuneration Report
in accordance with section 300A of the Corporations Act 2001. Our responsibility is to express an opinion on the
Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.
RSM AUSTRALIA PARTNERS
J S CROALL
Partner
Dated: 30 August 2019
Melbourne, Victoria
48
PARADIGM BIOPHARMACEUTICALS LIMITED
S H A R E H O L D E R I N F O R M A T I O N
Details of shares and options as at 21 August 2019:
Top holders
The 20 largest holders of each class of equity security as at 21 August 2019 were:
Fully paid ordinary shares
Name
No. of Shares
%
PAUL JOHN RENNIE
KZEE PTY LTD
CITICORP NOMINEES PTY LIMITED
J P MORGAN NOMINEES AUSTRALIA PTY LIMITED
HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED
CS FOURTH NOMINEES PTY LIMITED
MJGD NOMINEES PTY LTD
IRWIN BIOTECH NOMINEES PTY LTD
NANCY EDITH WILSON-GHOSH
MR BRETT LANGAN
V REDFORD PTY LTD
MR EVAN PHILIP CLUCAS + MS LEANNE JANE WESTON
JGM INVESTMENT GROUP PTY LTD
MR GRAEME ROY KAUFMAN
BRISPOT NOMINEES PTY LTD
HIMSTEDT & CO PTY LTD
VIEW 26 PTY LTD
CS THIRD NOMINEES PTY LIMITED
MS LENNA YU LING TYE
AUSTRALIAN EXECUTOR TRUSTEES LIMITED
11,733,468
10,781,467
7,933,844
6,910,375
6,412,284
6,096,639
5,400,216
4,406,113
3,910,935
3,130,672
2,505,419
2,427,913
2,185,715
2,074,250
1,982,059
1,921,871
1,728,671
1,599,156
1,510,540
1,437,500
6.10%
5.61%
4.13%
3.60%
3.34%
3.17%
2.81%
2.29%
2.03%
1.63%
1.30%
1.26%
1.14%
1.08%
1.03%
1.00%
0.90%
0.83%
0.79%
0.75%
Totals: Top 20 holders of ORDINARY FULLY PAID SHARES
Total Remaining Holders Balance
86,089,107
106,118,654
44.79%
55.21%
Distribution schedules
A distribution of each class of equity security as at 21 August 2019:
Fully paid ordinary shares
Range
Total holders
Units
% of Issued
Capital
1 - 1,000
1,001 - 10,000
10,001 - 100,000
100,001 - 500,000
500,001 - 1,000,000
1,000,001 - 20,000,000
Total
976
2,476
1,244
156
20
30
610,175
10,839,804
37,121,202
32,757,620
13,087,235
97,791,725
0.32
5.64
19.31
17.04
6.81
50.88
4902
192,207,761
100.00
49
PARADIGM BIOPHARMACEUTICALS LIMITED
S H A R E H O L D E R I N F O R M A T I O N ( C O N T ’ D )
Substantial shareholders
The names of substantial shareholders and the number of shares to which each substantial shareholder and their associates
have a relevant interest, as disclosed in substantial shareholding notices given to the Consolidated Entity, are set out below:
Substantial shareholder
Paul Rennie and related companies
Citicorp Nominees Pty Ltd
J P Morgan Nominees Australia Pty Limited
HSBC Custody Nominees (Australia) Limited
CS Fourth Nominees Pty Limited
MJGD Nominees Pty Ltd
Unmarketable parcels
Holdings less than a marketable parcel of ordinary shares (being 360 shares at 21 August 2019):
Holders
210
Voting Rights
Number of
Shares
23,414,935
7,933,844
6,910,375
6,412,284
6,096,639
5,400,216
Units
51,270
The voting rights attaching to ordinary shares are:
On a show of hands every member present in person or by proxy shall have one vote and upon a poll each share shall have
one vote.
Options do not carry any voting rights.
On-Market Buy Back
There is no current on-market buy-back.
50
PARADIGM BIOPHARMACEUTICALS LIMITED
C O R P O R A T E G O V E R N A N C E S T A T E M E N T
The Board and management of Paradigm Biopharmaceuticals Limited (Consolidated Entity) are committed to conducting
the business of the Consolidated Entity in an ethical manner and in accordance with the highest standards of corporate
governance. The Consolidated Entity has adopted and has substantially complied with the ASX Corporate Governance
Principles and Recommendations (Third Edition) to the extent appropriate to the size and nature of the Consolidated Entity's
operations.
This Corporate Governance Statement is accurate and up to date as at 30 June 2019 and has been approved by the Board
on 30 August 2019.
The Corporate Governance Statement is available on the Consolidated Entity’s website at:
http://www.paradigmbiopharma.com/investors/corporate-governance
51
PARADIGM BIOPHARMACEUTICALS LIMITED
END OF REPORT
52